WO2008084057A1 - Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition - Google Patents

Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition Download PDF

Info

Publication number
WO2008084057A1
WO2008084057A1 PCT/EP2008/050181 EP2008050181W WO2008084057A1 WO 2008084057 A1 WO2008084057 A1 WO 2008084057A1 EP 2008050181 W EP2008050181 W EP 2008050181W WO 2008084057 A1 WO2008084057 A1 WO 2008084057A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
disorders
compounds
formula
disorder
Prior art date
Application number
PCT/EP2008/050181
Other languages
French (fr)
Inventor
Josephus H. M. Lange
Cornelis G. Kruse
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Priority to MX2009007405A priority Critical patent/MX2009007405A/en
Priority to EA200970672A priority patent/EA200970672A1/en
Priority to KR1020097016686A priority patent/KR20090103932A/en
Priority to AU2008204456A priority patent/AU2008204456A1/en
Priority to EP08701345A priority patent/EP2111394A1/en
Priority to CN200880001916A priority patent/CN101809000A/en
Priority to JP2009545172A priority patent/JP2010515704A/en
Priority to BRPI0806452-0A priority patent/BRPI0806452A2/en
Priority to CA002671554A priority patent/CA2671554A1/en
Publication of WO2008084057A1 publication Critical patent/WO2008084057A1/en
Priority to IL198999A priority patent/IL198999A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to the fields of pharmaceutical and organic chemistry, and provides compounds with a combination of cannabinoid-CB-i antagonism and serotonin re-uptake inhibition, intermediates, formulations and methods.
  • a reductionist 'one target one disease' approach dominates the pharmaceutical industry for some decades. Using this strategy, many successful drugs were discovered. Despite that however, many diseases remain inadequately treated. These findings rationalize an alternative approach, wherein chemical entities are developed that simultaneously modulate multiple targets. Such drugs may show advantageous properties such as increased clinical efficacy, or lack of undesired pharmacokinetic drug-drug interactions, or unfavourable pharmacokinetic and pharmacodynamic properties. The latter may lead to unpredictable variability between individual patients. In order to combine different therapeutic mechanisms, cocktails of two or more drugs are still used in clinical practice. Alternatively, multicomponent drugs are being used wherein two or more pharmaceutically active compounds are co- formulated in a single tablet or capsule in order to improve patient compliance.
  • Another approach utilizes a pharmaceutical treatment with a chemical entity that is able to modulate more than one biological target simultaneously. It is clear that such a 'single entity — multiple target approach' offers the advantage of a lower risk of undesired drug-drug interactions compared to drug cocktails or multicomponent drugs.
  • Several multiple target ligands are known. The majority were found retrospectively or by accident: Only a few were rationally designed.
  • Cannabinoid receptors are part of the endo-cannabinoid system, involved in many diseases. Detailed information on cannabinoid receptors, CB 1 receptor modulators, and their pharmacological are found activities, are subjects of recent reviews (Landsman, 1997; Lichtman, 2002; De Petrocellis, 2004; Di Marzo, 2004; Hertzog, 2004; Lange, 2004, 2005; Smith, 2005; Thakur, 2005; Padgett, 2005; Muccioli, 2005; Lambert, 2005; Vandevoorde, 2005).
  • CB 1 receptor modulators include medicaments for treating psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, septic shock, glaucoma, diabetes, cancer, emesis, nausea, gastrointestinal disorders, gastric ulcers, diarrhoea, sexual disorders, impulse control disorders and cardiovascular disorders.
  • Mood disorders and anxiety disorders cause enormous suffering.
  • the introduction of selective serotonin reuptake inhibitors more than two decades ago has been a major step in the evolution of safer antidepressants.
  • Representative examples of selective serotonin reuptake inhibitors are fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram, zimeldine, clomipramine, indalpine and indatraline.
  • most selective serotonin reuptake inhibitors are mono-amine-based: They contain a basic nitrogen atom (Pacher, 2004).
  • the compounds of the invention can be used for treating: addiction, alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischaemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelinisation related disorders, diabetes, diabetic neuropathy, diarrhoea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder,
  • the compounds of the invention are particularly useful for treating: psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders.
  • the pharmacophore of the majority of cannabinoid CB 1 receptor antagonists was the subject of several reviews (Lange, 2005; Reggio, 2003). Scheme 1 visualizes it.
  • Ar 1 and Ar 2 represent phenyl groups, optionally substituted with one or two halogen atoms, trifluoromethyl groups, or methoxy groups.
  • the 'spacer' contains a five-membered heterocyclic group such as 4,5-dihydropyrazole, imidazole, pyrazole, thiazole, thiophene or pyrrole, or the spacer contains a phenyl group or a six-membered heterocyclic group such as pyridine, pyrimidines or pyrazine.
  • the spacer can also contain a azetidine moiety, a 1 ,3-benzodioxole moiety or an alkyl moiety like in MK-0364 (see below).
  • one of the aromatic groups can be fused to the spacer, or can be connected to the spacer by an additional ring: so-called conformational constraint.
  • conformational constraint Several kinds of conformational constraints have successfully been implemented in this pharmacophore model.
  • the H-bond acceptor represents a carbonyl group, a sulfonyl group or a nitrogen-atom which might be embedded in a heterocyclic ring structure such as an imidazole ring.
  • 'Lip' represents a lipophilic moiety, for instance piperidin-1-ylamino, pyrrolidinyl-1 -amino, cycloalkylamino, phenylamino, arylamino, benzylamino or alkylamino.
  • CB 1 receptor antagonist pharmacophore model a number of concrete examples of CB 1 receptor are depicted below.
  • the putative hydrogen bond acceptor atom oxygen atom from a carbonyl group, oxygen atom from a sulfonyl group, or N atom in a heteroaromatic ring is indicated bold.
  • the basic amino function may be unsubstituted (Ri and R 2 represent hydrogen) like in fluvoxamine, or mono substituted like in fluoxetine, indatraline and sertraline, or disubstituted like in citalopram, zimeldine and clomipramine.
  • the basic nitrogen atom may be part of a six-membered ring such as in indalpine and paroxetine: i.e. Ri represents a hydrogen atom and R 2 is part of the pharmacophore carbocyclic framework.
  • the selective CB 1 receptor antagonist SR141716A (rimonabant) is known for more than a decade. Many other selective CB 1 antagonists were invented later. Serotonin reuptake inhibitors are known for more than two decades. No compounds have hitherto been disclosed that combine CB 1 receptor antagonism with serotonin reuptake inhibitor activity.
  • the objective of the present invention was to develop compounds with a combination of CB 1 antagonism and serotonin reuptake inhibition.
  • This invention relates to compounds with a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, in particular to compounds having a pK-value > 6.00 in both CB 1 receptor binding and serotonin reuptake binding.
  • the invention relates to compounds of formula (1 ):
  • - A represents an essential structural element of any known cannabinoid-CB-i antagonist containing at least two phenyl rings that are independently optionally substituted with one or two substituents selected from halogen, methoxy and trifluoromethyl, said essential structural element being attached to a hydrogen bond acceptor in said cannabinoid-CBi antagonist, wherein the hydrogen bond acceptor moiety is either a carbonyl group, a sulfonyl group, or a nitrogen or oxygen atom incorporated in a heteroaromatic ring structure,
  • N represents a non-basic nitrogen atom
  • - T represents a saturated or unsaturated carbon chain of 0-8 atoms, wherein one carbon atom may be replaced with a nitrogen atom, optionally substituted with an (d-C 3 )-alkyl or CH 2 CF 3 group, or replaced with an oxygen atom or a sulphur atom, and which chain is optionally substituted with one or more substituents selected from fluoro, amino, cyano, (Ci-C 3 )alkyl, (Ci-C 3 )alkoxy and trifluoromethyl,
  • R represents hydrogen atom, or a (CrC 3 )-alkyl group, or R together with the nitrogen atom to which it is attached, and together with a part of T, forms a (C 4 -C 7 )-heterocycloalkyl or a heteroaryl group,
  • - B represents an essential structural element of any known serotonin reuptake inhibititor.
  • inventions provide one or more compounds of formula (1 ) wherein said cannabinoid- CB 1 antagonist is selected from: 1 1 C-JHU-75528, A-796260, ajulemic acid, AM 251 , AM 630, AVE-1625, CP- 272871 , CP-945598, EMD-68843, GRC-10389, LY-2077855, LY-320135, NIDA- 41020, O-2093, SLV319, SLV326, SR-140098, SR-144385, SR-41716A (rimonabant), surinabant, V-24343, WIN-54461 and WIN-56098,
  • said 5-HT reU ptake inhibitor is selected from:
  • NS-23459 omiloxetine, OPC-14523, opipramol, Org-6582, paroxetine, pramipexole, PRC-025, propizepine, quetiapine, quinupramine, ramelteon, R- fluoxetine, rizatriptan, robalzotan, roxindole, RS-1439, SB-649915, S-9977, SD- 726, selegiline, SEP-225289, SEP-227162, sertraline, sibutramine, (S)- sibutramine, (R)-didemethylsibutramine, SLV310, SLV314, SPD-473, tramadol, trazodone, udenafil, UK-416244, UP-23761 , VANH-36, venlafaxine, vilazodone, VML-670, VN-2222, volinanserin, WF-23, Wf-516, WL
  • A represents one of the fragments (A 1a ), (A 1b ), (A 2 ), (A 3 ) (A 4 ), (A 5 ), (A 6 ), (A 7 ), or (A 8 ):
  • X represents a sulfonyl or a carbonyl group
  • the "+" symbol represents the point at which the fragment is attached to moiety N (wherein N represents a non-basic nitrogen atom) in formula (1 )
  • R 1 , R 2 and R 3 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms
  • R 4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, Ci -3 -dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group
  • the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A 1a ), (A 1b ), (A 2 ), (A 3 ) (A 4 ), (A 5 ), (A 6 ), (A 7 ), or (A 8 ), and the NRTB sequence of formula (1 ) is one of the fragments (NTRB 1 ), (NRTB 2 ), (NTRB 3 ), (NRTB 4 ), (NTRB 5 ), (NRTB 6 ), (NTRB 7 ), (NRTB 8 ), (NTRB 9 ) or (NRTB 10 ):
  • R represents a hydrogen atom or a (Ci-C 3 )-alkyl group.
  • the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A 1a ) or (A 2 ):
  • R 1 , R 2 and R 3 independently represent hydrogen, trifluoromethyl or halogen
  • R 4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, Ci -3 -dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group, and the other symbols have the meanings as given above.
  • the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A 1a ) or (A 2 ), and the NRTB sequence of formula (1 ) is one of the fragments (NTRB 1 ), (NRTB 2 ), (NTRB 3 ), (NRTB 4 ), (NTRB 5 ), (NRTB 6 ), (NTRB 7 ), (NRTB 8 ), (NTRB 9 ) or (NRTB 10 ).
  • the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A 3 ) or (A 4 ):
  • the NRTB sequence of formula (1 ) is one of the fragments (NTRB 1 ), (NRTB 2 ), (NTRB 3 ), (NRTB 4 ), (NTRB 5 ), (NRTB 6 ), (NTRB 7 ), (NRTB 8 ), (NTRB 9 ) or (NRTB 10 ).
  • the invention relates to compounds of formula (1 ) that are:
  • the compounds of the invention of the general formula (1 ), as well as the pharmacologically acceptable salts thereof, have a combination of cannabinoid-CB-i antagonism and serotonin reuptake inhibition. They are useful in the treatment of disorders in which cannabinoid-CBi receptors and serotonin reuptake sites are involved, or that can be treated via manipulation of those receptors.
  • addiction for instance in: addiction, alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischaemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelinisation related disorders, diabetes, diabetic neuropathy, diarrhoea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain
  • a pharmaceutical composition for treating for example, a disorder or condition that may be treated by a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, the composition comprising a compound of formula (1 ), and a pharmaceutically acceptable carrier; a method of treatment of a disorder or condition that may be treated by a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, the method comprising administering to a mammal in need of such treatment a compound of formula (1 a pharmaceutical composition for treating, for example, a disorder or condition selected from the disorders listed herein; a method of treatment of a disorder or condition selected from the disorders listed herein, the method comprising administering to a patient in need of such treatment a compound of formula (1 ); a pharmaceutical composition for treating a disorder or condition selected from the disorders listed herein, the composition comprising a compound of formula(1 ), and a pharmaceutically acceptable carrier; a method for treating a disorder or condition selected from the disorders listed
  • the invention also provides the use of a compound according to formula (1 ) for the manufacture of a medicament.
  • the invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
  • a compound of the invention or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
  • Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compounds of the invention.
  • the invention also provides compounds, pharmaceutical compositions, kits and methods for treating a disorder or condition selected from the disorders listed herein, the method comprising administering to a patient in need of such treatment a compound of formula (1 ).
  • the compounds of the invention possess combination of cannabinoid-CB-i antagonism and serotonin reuptake inhibition.
  • the (ant)agonizing /inhibiting activities of the compounds of the invention is readily demonstrated, for example, using one or more of the assays described herein or known in the art.
  • the invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.
  • Isolation and purification of the compounds and intermediates described herein can be affected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick- layer chromatography, preparative low or high-pressure liquid chromatography, or a combination of these procedures.
  • suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.
  • the compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds.
  • Formula (1 ) shows the structure of the class of compounds without preferred stereochemistry.
  • the coupling reaction is often the formation of salts using an enantiomerically pure acid or base, such as for example (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L- tartaric acid
  • the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
  • the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
  • any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
  • Cis and trans isomers of the compound of formula (1 ) or a pharmaceutically acceptable salt thereof are also within the scope of the invention, and this also applies to tautomers of the compounds of formula (1 ) or a pharmaceutically acceptable salt thereof.
  • crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
  • Isotopically-labeled compound of formula (1 ) or pharmaceutically acceptable salts thereof including compounds of formula (1 ) isotopically-labeled to be detectable by PET or SPECT, are also included within the scope of the invention, and same applies to compounds of formula (1 ) labeled with [ 13 C]-, [ 14 C]-, [ 18 F]-, [ 3 H]-, [ 125 I]- or other isotopically-enriched atoms, suitable for receptor binding or metabolism studies.
  • the compounds of the invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction and disease.
  • a compound of the present invention is at least 10 times more potent as cannabinoid-CBi antagonist than as agonist or antagonist on any other receptor. Preferred are compounds with a 100-fold selectivity, most preferred are compounds with a selectivity of a factor 1 ,000 or higher.
  • a compound with serotonin re-uptake inhibiting acitivity' or 'serotonin re-uptake inhibitor' refer to a compounds having this activity — measured by unambiguous and well accepted pharmacological assays, including those described herein — without displaying substantial cross-reactivity towards another re-uptake site.
  • a compound of the present invention is at least 10 times more potent as serotonin re-uptake inhibitor than as inhibitor of the re-uptake of any other neurotransmitter.
  • antagonism and serotonin re-uptake inhibitory activity' refers to compounds having both activities — measured by unambiguous and well accepted pharmacological assays, including those described herein — without displaying substantial cross-reactivity towards other receptors or re-uptake sites.
  • a compound of the present invention is at least 10 times more potent as cannabinoid-CB-i antagonist and as serotonin re-uptake inhibitor, than as agonist or antagonist on any other receptor or as inhibitor of any other re-uptake site.
  • alkyl denotes a univalent saturated, branched or straight, hydrocarbon chain. Unless otherwise stated, such chains can contain from 1 to 18 carbon atoms.
  • alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, te/f-butyl, pentyl, isopentyl, neopentyl, te/f-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like.
  • the alkyl group When qualified 'lower', the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term 'alkane', and to derivative terms such as 'alkoxy'.
  • the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C x -Cy defines the number of carbon atoms present from the integer "x" to the integer "y” inclusive.
  • ⁇ lkyl(Ci -3 )' for example, means methyl, ethyl, n-propyl or isopropyl
  • 'alkyl(Ci -4 )' means 'methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl or 2-methyl-n-propyl'.
  • acyl means alkyl(d -3 ) carbonyl, arylcarbonyl or aryl-alkyl(Ci -3 )carbonyl.
  • 'Aryl' embraces monocyclic or fused bicyclic aromatic or hetero-aromatic groups, including but not limited to furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazo[2,1-b][1 ,3]thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,3,5-triazinyl, phenyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzo[b]furanyl, 1 ,2,3,4-tetrahydro-naphtyl, 1
  • 'Halo' or 'Halogen' means chloro, fluoro, bromo or iodo; 'hetero' as in 'heteroalkyl, heteroaromatic' etc. means containing one or more N, O or S atoms, 'heteroalkyl' includes alkyl groups with heteroatoms in any position, thus including N-bound O-bound or S-bound alkyl groups.
  • substituted means that the specified group or moiety bears one or more substituents. Where any group may carry multiple substituents, and a variety of possible substituents is provided, the substituents are independently selected, and need not to be the same.
  • unsubstituted means that the specified group bears no substituents.
  • substituents the term “independently” means that when more than one of such substituents are possible, they may be the same or different from each other.
  • amino refers to a nitrogen atom that may be either terminal, or a linker between two other groups, wherein the group may be a primary, secondary or tertiary (two hydrogen atoms bonded to the nitrogen atom, one hydrogen atom bonded to the nitrogen atom and no hydrogen atoms bonded to the nitrogen atom, respectively) amine.
  • sulfinyl and sulfonyl as used herein as part of another group respectively refer to an -SO- or an - SO 2 - group.
  • the terms 'compound' or 'compounds' include tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmacologically acceptable salts, hydrates or solvates, also when not explicitly mentioned.
  • the term "leaving group” (L) shall mean a charged or uncharged atom or group that departs during a substitution or displacement reaction.
  • the term refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile.
  • Such leaving groups are well known in the art. Examples include, but are not limited to, N- hydroxysuccinimide, N-hydroxybenzotriazole, halides (Br, Cl, I), triflates, mesylates, tosylates, and the like.
  • N-oxides of the compounds mentioned above belong to the invention.
  • Tertiary amines may or may not give rise to N-oxide metabolites. The extent to what N-oxidation takes place varies from trace amounts to a near quantitative conversion.
  • N-oxides may be more active than their corresponding tertiary amines, or less active. Whilst N-oxides can easily be reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees.
  • Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases conversion is a mere trace reaction, or even completely absent (Bickel, 1969).
  • any compound metabolized in vivo to provide the bioactive agent i.e., the compound of formula (1 )
  • Prodrugs are therapeutic agents, inactive per se but transformed into one or more active metabolites.
  • the terms "administering" and “use in the treatment of” shall encompass treating the various disorders described with the compound specifically disclosed, or with a compound that not specifically disclosed, but that converts to the specified compound in vivo after administration to the patient.
  • Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule.
  • Prodrugs i.e. compounds that when administered to humans or mammals by any known route, are metabolised to compounds having formula (1 ), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups.
  • Such compounds can be reacted with organic acids to yield compounds having formula (1 ) wherein an additional group is present that is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
  • an additional group is present that is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
  • 'Crystal form' refers to various solid forms of the same compound, for example polymorphs, solvates and amorphous forms.
  • 'Polymorphs' are crystal structures in which a compound can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Polymorphism is a frequently occurring phenomenon, affected by several crystallization conditions such as temperature, level of supersaturation, the presence of impurities, polarity of solvent, rate of cooling. Different polymorphs usually have different X-ray diffraction patterns, solid state NMR spectra, infrared or Raman spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility.
  • Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate.
  • 'Solvates' are generally a crystal form that contains either stoichiometric or non-stoichiometric amounts of a solvent. Often, during the process of crystallization some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. When the solvate is water, 'hydrates' may be formed.
  • the compound of formula (1 ) and pharmaceutically acceptable salts thereof may exist in the form of a hydrate or a solvate, and such a hydrate and solvate are also encompassed in the present invention.
  • the word “comprise” and variations of the word, such as “comprising” and “comprises” is not intended to exclude other additives, components, integers or steps. While it may be possible for the compounds of formula (1 ) to be administered as the raw chemical, it is preferable to present them as a 'pharmaceutical composition'. According to a further aspect, the present invention provides a pharmaceutical composition comprising at least one compound of formula (1 ), at least one pharmaceutically acceptable salt or solvate thereof, or a mixture of any of the foregoing, together with one or more pharmaceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients.
  • composition encompasses a product comprising specified ingredients in predetermined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts.
  • compositions encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the pharmaceutical composition includes enough of the active object compound to produce the desired effect upon the progress or condition of diseases.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • affinity of the compounds of the invention for CB 1 receptors and 5-HT reuptake sites was determined as described below.
  • the dose of the compound to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician.
  • the dosage will preferably be in the range of from 0.01 mg/kg to 10 mg/kg.
  • the typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient, and may be determined by a physician.
  • total daily dose administration to a patient in single or individual doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily, and more usually from 0.01 to 1 ,000 mg per day, of total active ingredients.
  • Such dosages will be administered to a patient in need of treatment from one to three times each day, or as often as needed for efficacy, and for periods of at least two months, more typically for at least six months, or chronically.
  • terapéuticaally effective amount refers to an amount of a therapeutic agent to treat a condition treatable by administrating a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or ameliorative response in a tissue system, animal or human. The effect may include, for example, treating the conditions listed herein.
  • the precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician (researcher, veterinarian, medical doctor or other clinician), and the therapeutics, or combination of therapeutics, selected for administration. Thus, it is not useful to specify an exact effective amount in advance.
  • pharmaceutically acceptable salt refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well-known in the art. They can be prepared in situ when finally isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids ⁇ Berge, 1977). The 'free base' form may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional matter.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • 'Complex' refers to a complex of the compound of the invention, e.g. formula (1 ), complexed with a metal ion, where at least one metal atom is chelated or sequestered. Complexes are prepared by methods well known in the art (Dwyer, 1964).
  • treatment refers to any treatment of a mammalian, for example human condition or disease, and includes: (1 ) inhibiting the disease or condition, i.e., arresting its development, (2) relieving the disease or condition, i.e., causing the condition to regress, or (3) stopping the symptoms of the disease.
  • the term 'inhibit' includes its generally accepted meaning which includes prohibiting, preventing, restraining, alleviating, ameliorating, and slowing, stopping or reversing progression, severity, or a resultant symptom.
  • the present method includes both medical therapeutic and/or prophylactic administration, as appropriate.
  • the term "medical therapy” intendeds to include prophylactic, diagnostic and therapeutic regimens carried out in vivo or ex vivo on humans or other mammals. 'Mammals' include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and humans, the latter being preferred.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • Nuclear magnetic resonance spectra ( 1 H NMR and 13 C NMR, APT) were determined in the indicated solvent using a Bruker ARX 400 ( 1 H: 400 MHz, 13 C: 100 MHz) at 300 K, or a Bruker (300 MHz) unless indicated otherwise.
  • the spectra were determined in deuterated chloroform or DMSO-d ⁇ obtained from Cambridge Isotope Laboratories Ltd. Chemical shifts ( ⁇ ) are given in ppm downfield from tetramethylsilane ( 1 H, 13 C) or CCI 3 F ( 19 F). Coupling constants J are given in Hz.
  • Peakshapes in the NMR spectra are indicated with the symbols 'q' (quartet), 'dq' (double quartet), T (triplet), 'dt' (double triplet), 'd' (doublet), 'dd' (double doublet), 's' (singlet), 'br s' (broad singlet) and 'rr ⁇ (multiplet).
  • Dichloromethane phosphorous pentoxide and calciumhydride
  • tetrahydrofuran sodium/ benzophenone ketyl
  • light petroleum 60-80
  • a compound of general formula (A 1a1 ) can be reacted with POCI3 in the presence of DMAP in an inert organic solvent such as dichloromethane to give the corresponding derivative of general formula (A 1a2 ).
  • This compound of general formula (A 1a2 ) can be reacted with a compound of general formula HRN-TB.
  • This reaction can give a compound of general formula (1 ) wherein A has the meaning as given herein above for (A 1a ) and wherein R, N, T and B have the abovementioned meaning
  • a compound of general formula (A 1b1 ) can be reacted with POCI 3 in the presence of DMAP in an inert organic solvent such as dichloromethane to give the corresponding chloride derivative of general formula (A 1b2 ).
  • This compound of general formula (A 1b2 ) can be reacted with a compound of general formula HRN-TB.
  • This reaction can give a compound of general formula (1 ) wherein A has the meaning as given herein above for (A 1b ) and wherein R, N, T and B have the abovementioned meaning.
  • R 1 and R 2 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms
  • R 4 represents a hydrogen or halogen atom or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methyl- sulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, d- 3 -dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1 -ylmethyl, morpholin-4-ylmethyl and the other symbols have the meanings as given above.
  • An ester of general formula (A 2 ' 1 ) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A 2 .
  • Such a reaction can be catalyzed by trimethylaluminum (AIMe 3 ) (Levin, 1982).
  • a compound of general formula (A 2 ' 1 ) can be hydrolyzed into the corresponding carboxylic acid of general formula (A 2 ' 2 ).
  • a compound of general formula (A 2 ' 2 ) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A 2 .
  • This reaction preferably proceeds via activating and coupling methods such as formation of an active ester, or in the presence of a so-called coupling reagent, for example, DCC, HBTU, TBTU, HOAt, PyBOP, BOP, CIP, 2-chloro-1 ,3- dimethyl-imidazolinium chloride, PyAOP and the like.
  • a so-called coupling reagent for example, DCC, HBTU, TBTU, HOAt, PyBOP, BOP, CIP, 2-chloro-1 ,3- dimethyl-imidazolinium chloride, PyAOP and the like.
  • a compound of general formula (A 2 ' 2 ) can be converted in the presence of a chlorinating agent such as thionyl chloride or oxalyl chloride into the corresponding acid chloride of general formula (A 2 ' 3 ).
  • a compound of general formula (A 2 ' 3 ) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A 2 .
  • a base like DIPEA can be added to the reaction mixture to scavenge the liberated hydrochloric acid or excess HRN-TB can be applied for this purpose.
  • the substructures of general formula (A 3 ) (A 4 ), (A 5 ), (A 6 ), (A 7 ), or (A 8 ), as given above, can be converted into compounds of the general formula (1 ) wherein part A is derived from the substructures (A 3 ) (A 4 ), (A 5 ), (A 6 ), (A 7 ), or (A 8 ) respectively.
  • salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid or an organic acid.
  • a suitable acid for instance an inorganic acid or an organic acid.
  • Toluene-4-sulfonic acid 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl ester (1.82 gram, 3.835 mmol) was dissolved in a magnetically stirred solution of 7 M NH 3 in methanol (30 ml) and stirred at room temperature for 72 hours. After removal of the solvent in vacuo the residue was dissolved again in dichloromethane and washed with saturated aqueous NaHCC>3. The organic layer was subsequently dried over Na 2 SO 4 , filtered and concentrated in vacuo to give crude 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptylamine (1.43 gram) which was not further purified.
  • Part B 4-Chloro-N- ⁇ [3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-[7-(4-fluoro- phenyl)-7,7-dimethoxyheptylamino] methylene ⁇ -benzenesulfonamide (0.200 gram, 0.258 mmol) was dissolved in a 1 :1 mixture of THF/methanol (30 ml) and 5 ml 1 N hydrochloric acid was added and the resulting mixture was stirred at room temperature for 20 hours. The mixture was quenched with 5 % aqueous NaHCO 3 .
  • Part C 4-Chloro-N- ⁇ [3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-[7-(4-fluoro- phenyl)-7-oxo-heptylamino] methylene ⁇ benzenesulfonamide (0.203 gram, 0.278 mmol) was dissolved in absolute ethanol (10 ml) and O-(2-aminoethyl)hydroxylamine dihydrochloride (61 mg, 1.5 mol equivalent) and pyridine (0.04 ml) were successively added. The resulting mixture was stirred at reflux temperature for 20 hours. The mixture was allowed to attain room temperature.
  • Ethyl 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylate was obtained according to WO03040107.
  • a magnetically stirred solution of ethyl 2-(2- chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylate (5.80 g, 0.0149 mol) in tetrahydrofuran (40 ml) was added a solution of LiOH (0.715 g) in water (40 ml). The resulting mixture was heated at 70 0 C for 16 hours.
  • the affinity of the compounds of the invention for cannabinoid CB 1 receptors can be determined using membrane preparations of CHO cells in which the human cannabinoid CB 1 receptor is stably transfected in conjunction with [ 3 H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [ 3 H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
  • Affinity of the compounds for serotonin reuptake sites was determined using the receptor binding assay described (Habert, 1985).
  • Cannabinoid-CB-i receptor affinity data and serotonin reuptake inhibition data obtained according to the protocols given above are shown in the table below.
  • compounds of formula (1 ) are formulated into pharmaceutical compositions that are important and novel embodiments of the invention because they contain the compounds, more particularly specific compounds disclosed herein.
  • Types of pharmaceutical compositions that may be used include, but are not limited to, tablets, chewable tablets, capsules (including microcapsules), solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, and other types disclosed herein, or are apparent to a person skilled in the art from the specification and general knowledge in the art.
  • the active ingredient for instance, may also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.
  • compositions are used for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or other ways to administer.
  • the pharmaceutical formulation contains at least one compound of formula (1 ) in admixture with at least one pharmaceutically acceptable adjuvant, diluent and/or carrier.
  • the total amount of active ingredients suitably is in the range of from about 0.1% (w/w) to about 95% (w/w) of the formulation, suitably from 0.5% to 50% (w/w) and preferably from 1% to 25% (w/w). In some embodiments, the amount of active ingredient is greater than about 95% (w/w) or less than about 0.1 % (w/w).
  • the compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
  • auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
  • auxiliary substances include magnesium carbonate, titanium dioxide, lactose, saccharose, sorbitol, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, amylopectin, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • the mixture may then be processed into granules or pressed into tablets.
  • a tablet is prepared using the ingredients below:
  • Total 230 The components are blended and compressed to form tablets each weighing 230 mg.
  • the active ingredients may be separately premixed with the other non-active ingredients, before being mixed to form a formulation.
  • the active ingredients may also be mixed with each other, before being mixed with the non-active ingredients to form a formulation.
  • Soft gelatin capsules may be prepared with capsules containing a mixture of the active ingredients of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules.
  • Hard gelatin capsules may contain granules of the active ingredients.
  • Hard gelatin capsules may also contain the active ingredients together with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories that contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule that contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations may be prepared in the form of syrups, elixirs, concentrated drops or suspensions, e.g. solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents.
  • Liquid preparations may also be prepared in the form of a dry powder, reconstituted with a suitable solvent prior to use. Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation, reconstituted with a suitable solvent before use.
  • formulations and 'kits of parts' comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention, for use in medical therapy.
  • container(s) can be written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
  • formulations of the invention in the manufacture of medicaments for treating a condition wherein antagonism of CB 1 receptors and/or inhibition of serotonin re-uptake is required or desired, and methods of medical treatment or comprising the administration of a therapeutically effective total amount of at least one compound of formula (1 ), either as such or, in the case of prodrugs, after administration, to a patient suffering from, or susceptible to, a condition wherein antagonism of CB 1 receptors and/or inhibition of serotonin re-uptake is required or desired
  • compositions comprising preferred active compounds for systemic use or topical application.
  • Other compounds of the invention or combinations thereof may be used in place of (or in addition to) said compounds.
  • concentration of the active ingredient may be varied over a wide range as discussed herein.
  • the amounts and types of ingredients that may be included are well known in the art.
  • Bodanszky M. and A. Bodanszky: The Practice of Peptide Synthesis, Springer-Verlag, New
  • Ettmayer P. et al., "Lessons learned from marketed and investigational prodrugs", J. Med. Chem., 47, 2393-2404, 2004. Habert, E. et al.,: “Characterisation of [ 3 H]-paroxetine binding to rat cortical membranes", Eur.J.Pharmacol., 118, 107-1 14, 1985.

Abstract

This invention relates to compounds with a combination of cannabinoid-CB1antagonism and serotonin reuptake inhibition to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders. In particular the invention relates to compoundsof the general formula (I): wherein the symbols have the meanings given in the specification.

Description

COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND
SEROTONIN REUPTAKE INHIBITION
TECHNICAL FIELD
This invention relates to the fields of pharmaceutical and organic chemistry, and provides compounds with a combination of cannabinoid-CB-i antagonism and serotonin re-uptake inhibition, intermediates, formulations and methods.
BACKGROUND ART
A reductionist 'one target — one disease' approach dominates the pharmaceutical industry for some decades. Using this strategy, many successful drugs were discovered. Despite that however, many diseases remain inadequately treated. These findings rationalize an alternative approach, wherein chemical entities are developed that simultaneously modulate multiple targets. Such drugs may show advantageous properties such as increased clinical efficacy, or lack of undesired pharmacokinetic drug-drug interactions, or unfavourable pharmacokinetic and pharmacodynamic properties. The latter may lead to unpredictable variability between individual patients. In order to combine different therapeutic mechanisms, cocktails of two or more drugs are still used in clinical practice. Alternatively, multicomponent drugs are being used wherein two or more pharmaceutically active compounds are co- formulated in a single tablet or capsule in order to improve patient compliance. Another approach utilizes a pharmaceutical treatment with a chemical entity that is able to modulate more than one biological target simultaneously. It is clear that such a 'single entity — multiple target approach' offers the advantage of a lower risk of undesired drug-drug interactions compared to drug cocktails or multicomponent drugs. Several multiple target ligands are known. The majority were found retrospectively or by accident: Only a few were rationally designed.
Cannabinoid receptors are part of the endo-cannabinoid system, involved in many diseases. Detailed information on cannabinoid receptors, CB1 receptor modulators, and their pharmacological are found activities, are subjects of recent reviews (Landsman, 1997; Lichtman, 2002; De Petrocellis, 2004; Di Marzo, 2004; Hertzog, 2004; Lange, 2004, 2005; Smith, 2005; Thakur, 2005; Padgett, 2005; Muccioli, 2005; Lambert, 2005; Vandevoorde, 2005). Potential therapeutic applications of CB1 receptor modulators disclosed in the quoted reviews include medicaments for treating psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, septic shock, glaucoma, diabetes, cancer, emesis, nausea, gastrointestinal disorders, gastric ulcers, diarrhoea, sexual disorders, impulse control disorders and cardiovascular disorders.
Mood disorders and anxiety disorders cause enormous suffering. The introduction of selective serotonin reuptake inhibitors more than two decades ago has been a major step in the evolution of safer antidepressants. Representative examples of selective serotonin reuptake inhibitors are fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram, zimeldine, clomipramine, indalpine and indatraline. In spite of the remarkable structural diversity, most selective serotonin reuptake inhibitors are mono-amine-based: They contain a basic nitrogen atom (Pacher, 2004). Scientific articles, patents and patent applications indicate the following therapeutic applications for serotonin reuptake inhibitors: alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, bentral nervous system disease, chemotherapy induced emesis, cocaine addiction, cognitive disorder, diabetic neuropathy, drug dependence, eating disorder, female sexual dysfunction, functional bowel disorder, generalized anxiety disorder, headache, inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, menopause, migraine, myalgia, neuralgia, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain, panic disorder, Parkinson's disease, premature ejaculation, premenstrual syndrome, psychosexual disorder, psychosis, rheumatoid arthritis, schizophrenia, sleep disorder and urinary incontinence.
Because of the frequently observed co-morbidity of symptoms of different diseases, compounds combining cannabinoid-CBi antagonism with serotonin reuptake inhibition can be useful to treat the conditions wherein either a cannabinoid CB1 antagonist or a serotonin reuptake inhibitor is potentially effective. Thus the compounds of the invention can be used for treating: addiction, alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischaemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelinisation related disorders, diabetes, diabetic neuropathy, diarrhoea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain, panic disorder, Parkinson's disease, plaque sclerosis, premature ejaculation, premenstrual syndrome, psychosexual disorder, psychosis, rheumatoid arthritis, septic shock, schizophrenia, sexual disorders, sleep disorder, spinal cord injury, stroke, Tourette's syndrome, traumatic brain injury, tremor, urinary incontinence and viral encephalitis.
Of particular importance is the use of the compounds of the invention for treating disorders claimed to be treatable with cannabinoid CB1 antagonists as well as with serotonin reuptake inhibitors. Attacking such disorders simultaneously via two different mechanisms of action can have synergistic effects. Thus, the compounds of the invention are particularly useful for treating: psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders. The pharmacophore of the majority of cannabinoid CB1 receptor antagonists was the subject of several reviews (Lange, 2005; Reggio, 2003). Scheme 1 visualizes it.
Asp366-Lys192
Spacer H -bond acceptor Lip
Ar2
Schemel : CB1 receptor antagonist pharmacophore, and one of its putative key interactions with the CB1 receptor
In Scheme 1 , Ar1 and Ar2 represent phenyl groups, optionally substituted with one or two halogen atoms, trifluoromethyl groups, or methoxy groups. In Scheme 1 , the 'spacer' contains a five-membered heterocyclic group such as 4,5-dihydropyrazole, imidazole, pyrazole, thiazole, thiophene or pyrrole, or the spacer contains a phenyl group or a six-membered heterocyclic group such as pyridine, pyrimidines or pyrazine. The spacer can also contain a azetidine moiety, a 1 ,3-benzodioxole moiety or an alkyl moiety like in MK-0364 (see below). In addition, one of the aromatic groups can be fused to the spacer, or can be connected to the spacer by an additional ring: so-called conformational constraint. Several kinds of conformational constraints have successfully been implemented in this pharmacophore model. The H-bond acceptor represents a carbonyl group, a sulfonyl group or a nitrogen-atom which might be embedded in a heterocyclic ring structure such as an imidazole ring. In Scheme 1 , 'Lip' represents a lipophilic moiety, for instance piperidin-1-ylamino, pyrrolidinyl-1 -amino, cycloalkylamino, phenylamino, arylamino, benzylamino or alkylamino.
Molecular modeling studies indicate that the presence of a hydrogen bond acceptor is crucial: that is thought to interact with the Lys-192 amino acid residue side chain in the CB1 receptor, thereby stabilizing its inactive state.
To illustrate the CB1 receptor antagonist pharmacophore model, a number of concrete examples of CB1 receptor are depicted below. The putative hydrogen bond acceptor atom (oxygen atom from a carbonyl group, oxygen atom from a sulfonyl group, or N atom in a heteroaromatic ring) is indicated bold.
Figure imgf000006_0001
Rimonabant SR 147778 CP-272,871 NIDA-41020
Figure imgf000006_0002
SLV326 R = CF, A pharmacophore model of serotonin reuptake inhibitors has been reported (Bureau, 2002). Scheme 2 visualizes it:
Figure imgf000007_0001
Scheme 2: Schematic overview of the SRI pharmacophore
It is characterized by a basic nitrogen atom (N), a lipophilic extended aromatic region (Ar1) and a lipophilic part (Lip-SRI). The basic amino function may be unsubstituted (Ri and R2 represent hydrogen) like in fluvoxamine, or mono substituted like in fluoxetine, indatraline and sertraline, or disubstituted like in citalopram, zimeldine and clomipramine. The basic nitrogen atom may be part of a six-membered ring such as in indalpine and paroxetine: i.e. Ri represents a hydrogen atom and R2 is part of the pharmacophore carbocyclic framework. Many 4-(3-indolyl- alkyl)piperidine derivatives, including indalpine and 4-(3-indolyl-alkyl)piperazine derivatives have been shown to possess potent serotonin reuptake inhibitor activity (Le Fur, 1977; Malleron, 1993).
The selective CB1 receptor antagonist SR141716A (rimonabant) is known for more than a decade. Many other selective CB1 antagonists were invented later. Serotonin reuptake inhibitors are known for more than two decades. No compounds have hitherto been disclosed that combine CB1 receptor antagonism with serotonin reuptake inhibitor activity.
The objective of the present invention was to develop compounds with a combination of CB1 antagonism and serotonin reuptake inhibition. DISCLOSURE
It was found that molecules containing essential parts of known cannabinoid-CBi antagonists and essential parts of the known serotonin reuptake inhibitors indalpine or fluvoxamine, share the activity of both molecules from which they were derived: cannabinoid-CBi antagonism and serotonin reuptake inhibition. This invention relates to compounds with a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, in particular to compounds having a pK-value > 6.00 in both CB1 receptor binding and serotonin reuptake binding.
More in particular, the invention relates to compounds of formula (1 ):
R
. /N B (1 ) r\ I
or a tautomer, stereoisomer, N-oxide, isotopically-labelled analogue, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein:
- A represents an essential structural element of any known cannabinoid-CB-i antagonist containing at least two phenyl rings that are independently optionally substituted with one or two substituents selected from halogen, methoxy and trifluoromethyl, said essential structural element being attached to a hydrogen bond acceptor in said cannabinoid-CBi antagonist, wherein the hydrogen bond acceptor moiety is either a carbonyl group, a sulfonyl group, or a nitrogen or oxygen atom incorporated in a heteroaromatic ring structure,
- N represents a non-basic nitrogen atom,
- T represents a saturated or unsaturated carbon chain of 0-8 atoms, wherein one carbon atom may be replaced with a nitrogen atom, optionally substituted with an (d-C3)-alkyl or CH2CF3 group, or replaced with an oxygen atom or a sulphur atom, and which chain is optionally substituted with one or more substituents selected from fluoro, amino, cyano, (Ci-C3)alkyl, (Ci-C3)alkoxy and trifluoromethyl,
- R represents hydrogen atom, or a (CrC3)-alkyl group, or R together with the nitrogen atom to which it is attached, and together with a part of T, forms a (C4-C7)-heterocycloalkyl or a heteroaryl group,
- B represents an essential structural element of any known serotonin reuptake inhibititor.
Other embodiments provide one or more compounds of formula (1 ) wherein said cannabinoid- CB1 antagonist is selected from: 1 1 C-JHU-75528, A-796260, ajulemic acid, AM 251 , AM 630, AVE-1625, CP- 272871 , CP-945598, EMD-68843, GRC-10389, LY-2077855, LY-320135, NIDA- 41020, O-2093, SLV319, SLV326, SR-140098, SR-144385, SR-41716A (rimonabant), surinabant, V-24343, WIN-54461 and WIN-56098,
and said 5-HTreUptake inhibitor is selected from:
403U76, A-80426, AD-337, adinazolam, agomelatine, alaproclate, amineptine, amitriptyline, ARAK-0029, ARAK-0051 , befetupitant, befloxatone, BGC-20-1259, bicifadine, BMS-505130, brofaromine, bupropion, butriptyline, cericlamine, citalopram, CL:-275838, clomipramine, clovoxamine, CX-157, dapoxetine, desvenlafaxine, dexfenfluramine, dibenzepin, diclofensine, dosulepine, DOV- 21947, DOV-102677, DOV-216303, duloxetine, DU 125530, DuP-631 , EN-3215, EpiCept NP-1 , escitalopram, femoxetine, fluoxetine, (S)-fluoxetine, fluvoxamine, gepirone, IDN-5491 , imipramine, indalpine, iprindole, L-792239, LI-301 , litoxetine, lofepramine, LU-10134-C, LU-AA21004, lubazodone, LY-214281 , LY- 367265, LY-393558, maprotiline, MCI-225, MCL-0042, McN-5652, melitracen, mianserine, milnacipran, mirtazepine, moclobemide, modafinil, nefazodone, 6- nitroquipazine, nortriptyline, NR-200s, NS-2381 , NS-2389, NS-2463, NS-4194,
NS-23459, omiloxetine, OPC-14523, opipramol, Org-6582, paroxetine, pramipexole, PRC-025, propizepine, quetiapine, quinupramine, ramelteon, R- fluoxetine, rizatriptan, robalzotan, roxindole, RS-1439, SB-649915, S-9977, SD- 726, selegiline, SEP-225289, SEP-227162, sertraline, sibutramine, (S)- sibutramine, (R)-didemethylsibutramine, SLV310, SLV314, SPD-473, tramadol, trazodone, udenafil, UK-416244, UP-23761 , VANH-36, venlafaxine, vilazodone, VML-670, VN-2222, volinanserin, WF-23, Wf-516, WL-1011 , WL-1017, YM-922 and zimeldine.
Further embodiments provide one or more compounds of formula (1 ): wherein A represents one of the fragments (A1a), (A1b), (A2), (A3) (A4), (A5), (A6), (A7), or (A8):
Figure imgf000010_0001
Figure imgf000010_0002
wherein, X represents a sulfonyl or a carbonyl group, the "+" symbol represents the point at which the fragment is attached to moiety N (wherein N represents a non-basic nitrogen atom) in formula (1 ), R1, R2 and R3 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms, R4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, Ci-3-dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group, and the other symbols have the meanings as given above. In another embodiment the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A1a), (A1b), (A2), (A3) (A4), (A5), (A6), (A7), or (A8), and the NRTB sequence of formula (1 ) is one of the fragments (NTRB1), (NRTB2), (NTRB3), (NRTB4), (NTRB5), (NRTB6), (NTRB7), (NRTB8), (NTRB9) or (NRTB10):
Figure imgf000011_0001
wherein R represents a hydrogen atom or a (Ci-C3)-alkyl group. In another embodiment the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A1a) or (A2):
Figure imgf000012_0001
wherein, X represents a sulphonyl or a carbonyl group, + the point at which the fragment is attached to the non-basic nitrogen atom N in formula (1 ), R1, R2 and R3 independently represent hydrogen, trifluoromethyl or halogen, R4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, Ci-3-dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group, and the other symbols have the meanings as given above.
In another embodiment the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A1a) or (A2), and the NRTB sequence of formula (1 ) is one of the fragments (NTRB1), (NRTB2), (NTRB3), (NRTB4), (NTRB5), (NRTB6), (NTRB7), (NRTB8), (NTRB9) or (NRTB10).
In another embodiment the invention relates to compounds of formula (1 ) wherein A represents one of the fragments (A3) or (A4):
Figure imgf000012_0002
and the NRTB sequence of formula (1 ) is one of the fragments (NTRB1), (NRTB2), (NTRB3), (NRTB4), (NTRB5), (NRTB6), (NTRB7), (NRTB8), (NTRB9) or (NRTB10). In another embodiment the invention relates to compounds of formula (1 ) that are:
Figure imgf000013_0001
Figure imgf000013_0002
The compounds of the invention of the general formula (1 ), as well as the pharmacologically acceptable salts thereof, have a combination of cannabinoid-CB-i antagonism and serotonin reuptake inhibition. They are useful in the treatment of disorders in which cannabinoid-CBi receptors and serotonin reuptake sites are involved, or that can be treated via manipulation of those receptors. For instance in: addiction, alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischaemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelinisation related disorders, diabetes, diabetic neuropathy, diarrhoea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain, panic disorder, Parkinson's disease, plaque sclerosis, premature ejaculation, premenstrual syndrome, psychosexual disorder, psychosis, rheumatoid arthritis, septic shock, schizophrenia, sexual disorders, sleep disorder, spinal cord injury, stroke, Tourette's syndrome, traumatic brain injury, tremor, urinary incontinence and viral encephalitis.
Other embodiments of the invention include, but are not limited to:
a pharmaceutical composition for treating, for example, a disorder or condition that may be treated by a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, the composition comprising a compound of formula (1 ), and a pharmaceutically acceptable carrier; a method of treatment of a disorder or condition that may be treated by a combination of cannabinoid-CBi antagonism and serotonin reuptake inhibition, the method comprising administering to a mammal in need of such treatment a compound of formula (1 a pharmaceutical composition for treating, for example, a disorder or condition selected from the disorders listed herein; a method of treatment of a disorder or condition selected from the disorders listed herein, the method comprising administering to a patient in need of such treatment a compound of formula (1 ); a pharmaceutical composition for treating a disorder or condition selected from the disorders listed herein, the composition comprising a compound of formula(1 ), and a pharmaceutically acceptable carrier; a method for treating a disorder or condition selected from the disorders listed herein, the method comprising administering to a patient in need of such treatment a compound of formula (1 ). a method of antagonizing a cannabinoid-CBi antagonism receptor and inhibiting serotonin reuptake, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (1 );
The invention also provides the use of a compound according to formula (1 ) for the manufacture of a medicament.
The invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed. Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compounds of the invention.
The invention also provides compounds, pharmaceutical compositions, kits and methods for treating a disorder or condition selected from the disorders listed herein, the method comprising administering to a patient in need of such treatment a compound of formula (1 ).
The compounds of the invention possess combination of cannabinoid-CB-i antagonism and serotonin reuptake inhibition. The (ant)agonizing /inhibiting activities of the compounds of the invention is readily demonstrated, for example, using one or more of the assays described herein or known in the art. The invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.
Isolation and purification of the compounds and intermediates described herein can be affected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick- layer chromatography, preparative low or high-pressure liquid chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.
The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. Formula (1 ) shows the structure of the class of compounds without preferred stereochemistry. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base, such as for example (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L- tartaric acid The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art. Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
Cis and trans isomers of the compound of formula (1 ) or a pharmaceutically acceptable salt thereof are also within the scope of the invention, and this also applies to tautomers of the compounds of formula (1 ) or a pharmaceutically acceptable salt thereof.
Some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. Isotopically-labeled compound of formula (1 ) or pharmaceutically acceptable salts thereof, including compounds of formula (1 ) isotopically-labeled to be detectable by PET or SPECT, are also included within the scope of the invention, and same applies to compounds of formula (1 ) labeled with [13C]-, [14C]-, [18F]-, [3H]-, [125I]- or other isotopically-enriched atoms, suitable for receptor binding or metabolism studies. The compounds of the invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction and disease.
DEFINITIONS Within the context of this description, the terms 'compound with cannabinoid-CE÷H antagonism' and 'cannabinoid-CB.| antagonist' refer to compounds having this activity — measured by unambiguous and well accepted pharmacological assays, including those described herein — without displaying substantial cross-reactivity towards another receptor. In one embodiment, a compound of the present invention is at least 10 times more potent as cannabinoid-CBi antagonist than as agonist or antagonist on any other receptor. Preferred are compounds with a 100-fold selectivity, most preferred are compounds with a selectivity of a factor 1 ,000 or higher. The terms 'compound with serotonin re-uptake inhibiting acitivity' or 'serotonin re-uptake inhibitor' refer to a compounds having this activity — measured by unambiguous and well accepted pharmacological assays, including those described herein — without displaying substantial cross-reactivity towards another re-uptake site. In one embodiment, a compound of the present invention is at least 10 times more potent as serotonin re-uptake inhibitor than as inhibitor of the re-uptake of any other neurotransmitter. Preferred are compounds with a 100-fold selectivity, most preferred are compounds with a selectivity of a factor 1 ,000 or more. A compound 'having both cannabinoid-CB.| antagonism and serotonin re-uptake inhibitory activity', refers to compounds having both activities — measured by unambiguous and well accepted pharmacological assays, including those described herein — without displaying substantial cross-reactivity towards other receptors or re-uptake sites. In one embodiment, a compound of the present invention is at least 10 times more potent as cannabinoid-CB-i antagonist and as serotonin re-uptake inhibitor, than as agonist or antagonist on any other receptor or as inhibitor of any other re-uptake site. Preferred are compounds with a
100-fold selectivity, most preferred are compounds with a selectivity of a factor 1 ,000 or more.
General terms used in the description of compounds herein disclosed bear their usual meanings. The term alkyl as used herein denotes a univalent saturated, branched or straight, hydrocarbon chain. Unless otherwise stated, such chains can contain from 1 to 18 carbon atoms. Representative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, te/f-butyl, pentyl, isopentyl, neopentyl, te/f-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like. When qualified 'lower', the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term 'alkane', and to derivative terms such as 'alkoxy'. The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Cx-Cy defines the number of carbon atoms present from the integer "x" to the integer "y" inclusive. Αlkyl(Ci-3)' for example, means methyl, ethyl, n-propyl or isopropyl, and 'alkyl(Ci-4)' means 'methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl or 2-methyl-n-propyl'.
The term 'acyl' means alkyl(d-3) carbonyl, arylcarbonyl or aryl-alkyl(Ci-3)carbonyl. 'Aryl' embraces monocyclic or fused bicyclic aromatic or hetero-aromatic groups, including but not limited to furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazo[2,1-b][1 ,3]thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,3,5-triazinyl, phenyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzo[b]furanyl, 1 ,2,3,4-tetrahydro-naphtyl, 1 ,2,3,4-tetrahydroisoquinolinyl, indanyl, indenyl, benzo[b]thienyl, 2,3-dihydro-1 ,4-benzodioxin-5- yl, benzimidazolyl, benzothiazolyl, benzo[1 ,2,5]thia-diazolyl, purinyl, quinolinyl, isoquinolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, naphthyl, pteridinyl or azulenyl. 'Halo' or 'Halogen' means chloro, fluoro, bromo or iodo; 'hetero' as in 'heteroalkyl, heteroaromatic' etc. means containing one or more N, O or S atoms, 'heteroalkyl' includes alkyl groups with heteroatoms in any position, thus including N-bound O-bound or S-bound alkyl groups.
The term "substituted" means that the specified group or moiety bears one or more substituents. Where any group may carry multiple substituents, and a variety of possible substituents is provided, the substituents are independently selected, and need not to be the same. The term "unsubstituted" means that the specified group bears no substituents. With reference to substituents, the term "independently" means that when more than one of such substituents are possible, they may be the same or different from each other.
The terms "oxy", "thio" and "carbo" as used herein as part of another group respectively refer to an oxygen atom, a sulphur atom and a carbonyl (C=O) group, serving as linker between two groups, such as for instance hydroxyl, oxyalkyl, thioalkyl, carboxyalkyl, etc. The term "amino" as used herein alone, or as part of another group, refers to a nitrogen atom that may be either terminal, or a linker between two other groups, wherein the group may be a primary, secondary or tertiary (two hydrogen atoms bonded to the nitrogen atom, one hydrogen atom bonded to the nitrogen atom and no hydrogen atoms bonded to the nitrogen atom, respectively) amine. The terms "sulfinyl" and "sulfonyl" as used herein as part of another group respectively refer to an -SO- or an - SO2- group.
To provide a more concise description, the terms 'compound' or 'compounds' include tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmacologically acceptable salts, hydrates or solvates, also when not explicitly mentioned. As used herein, the term "leaving group" (L) shall mean a charged or uncharged atom or group that departs during a substitution or displacement reaction. The term refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples include, but are not limited to, N- hydroxysuccinimide, N-hydroxybenzotriazole, halides (Br, Cl, I), triflates, mesylates, tosylates, and the like.
N-oxides of the compounds mentioned above belong to the invention. Tertiary amines may or may not give rise to N-oxide metabolites. The extent to what N-oxidation takes place varies from trace amounts to a near quantitative conversion. N-oxides may be more active than their corresponding tertiary amines, or less active. Whilst N-oxides can easily be reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees. Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases conversion is a mere trace reaction, or even completely absent (Bickel, 1969).
Any compound metabolized in vivo to provide the bioactive agent (i.e., the compound of formula (1 )) is a prodrug within the scope and spirit of the application. Prodrugs are therapeutic agents, inactive per se but transformed into one or more active metabolites. Thus, in the methods of treatment of the present invention, the terms "administering" and "use in the treatment of" shall encompass treating the various disorders described with the compound specifically disclosed, or with a compound that not specifically disclosed, but that converts to the specified compound in vivo after administration to the patient. Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule. These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Bundgaard, 1985; King, 1994; Stella, 2004; Ettmayer, 2004; Jarvinen, 2005). Prodrugs, i.e. compounds that when administered to humans or mammals by any known route, are metabolised to compounds having formula (1 ), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1 ) wherein an additional group is present that is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
'Crystal form' refers to various solid forms of the same compound, for example polymorphs, solvates and amorphous forms. 'Polymorphs' are crystal structures in which a compound can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Polymorphism is a frequently occurring phenomenon, affected by several crystallization conditions such as temperature, level of supersaturation, the presence of impurities, polarity of solvent, rate of cooling. Different polymorphs usually have different X-ray diffraction patterns, solid state NMR spectra, infrared or Raman spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. 'Solvates' are generally a crystal form that contains either stoichiometric or non-stoichiometric amounts of a solvent. Often, during the process of crystallization some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. When the solvate is water, 'hydrates' may be formed. The compound of formula (1 ) and pharmaceutically acceptable salts thereof may exist in the form of a hydrate or a solvate, and such a hydrate and solvate are also encompassed in the present invention. Examples thereof include % hydrate, dihydrochloride dihydrate, and the like. 'Amorphous' forms are noncrystalline materials with no long range order, and generally do not give a distinctive powder X-ray diffraction pattern. Crystal forms in general have been described by Byrn (1995) and Martin (1995)
To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about". It is understood that whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.
Throughout the description and the claims of this specification the word "comprise" and variations of the word, such as "comprising" and "comprises" is not intended to exclude other additives, components, integers or steps. While it may be possible for the compounds of formula (1 ) to be administered as the raw chemical, it is preferable to present them as a 'pharmaceutical composition'. According to a further aspect, the present invention provides a pharmaceutical composition comprising at least one compound of formula (1 ), at least one pharmaceutically acceptable salt or solvate thereof, or a mixture of any of the foregoing, together with one or more pharmaceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The term "composition" as used herein encompasses a product comprising specified ingredients in predetermined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts. In relation to pharmaceutical compositions, this term encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. In general, pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. The pharmaceutical composition includes enough of the active object compound to produce the desired effect upon the progress or condition of diseases. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The affinity of the compounds of the invention for CB1 receptors and 5-HT reuptake sites was determined as described below. From the binding affinity measured for a given compound of formula (1 ), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured K-value, nearly 100% of the CB1 receptors likely will be occupied by the compound. By converting that concentration to mg of compound per kg of patient one obtains a theoretical lowest effective dose, assuming ideal bioavailability. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dose of the compound to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician. The dosage will preferably be in the range of from 0.01 mg/kg to 10 mg/kg. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient, and may be determined by a physician. In general, total daily dose administration to a patient in single or individual doses, may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily, and more usually from 0.01 to 1 ,000 mg per day, of total active ingredients. Such dosages will be administered to a patient in need of treatment from one to three times each day, or as often as needed for efficacy, and for periods of at least two months, more typically for at least six months, or chronically.
The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat a condition treatable by administrating a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or ameliorative response in a tissue system, animal or human. The effect may include, for example, treating the conditions listed herein. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician (researcher, veterinarian, medical doctor or other clinician), and the therapeutics, or combination of therapeutics, selected for administration. Thus, it is not useful to specify an exact effective amount in advance. The term "pharmaceutically acceptable salt" refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. They can be prepared in situ when finally isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids {Berge, 1977). The 'free base' form may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional matter. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention. 'Complex' refers to a complex of the compound of the invention, e.g. formula (1 ), complexed with a metal ion, where at least one metal atom is chelated or sequestered. Complexes are prepared by methods well known in the art (Dwyer, 1964).
The term "treatment" as used herein refers to any treatment of a mammalian, for example human condition or disease, and includes: (1 ) inhibiting the disease or condition, i.e., arresting its development, (2) relieving the disease or condition, i.e., causing the condition to regress, or (3) stopping the symptoms of the disease. The term 'inhibit' includes its generally accepted meaning which includes prohibiting, preventing, restraining, alleviating, ameliorating, and slowing, stopping or reversing progression, severity, or a resultant symptom. As such, the present method includes both medical therapeutic and/or prophylactic administration, as appropriate. As used herein, the term "medical therapy" intendeds to include prophylactic, diagnostic and therapeutic regimens carried out in vivo or ex vivo on humans or other mammals. 'Mammals' include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and humans, the latter being preferred. The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
ABBREVIATIONS
BOC te/f.-butoxycarbonyl BOP benzotriazol-1 -yl-oxytris-phosphonium hexafluorophosphate
CB1 cannabinoid receptor subtype-1
CB2 cannabinoid receptor subtype-2
CHO Chinese Hamster Ovary (cells)
CIP 2-chloro-1 ,3-dimethylimidazolinium hexafluorophosphate DCC dicyclohexylcarbodiimide
DIPEA diisopropylethylamine
DMAP 4-dimethylaminopyridin
DMSO dimethylsulfoxide
EDCI 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride HBTU O-benzotriazol-1 -yl-N,N,N',N'-tetramethyluronium hexafluorophosphate
HOAt N-hydroxy-7-azabenzotriazole mg milligram(s) min minute(s)
PET positron emission tomography PyAOP 7-azabenzotriazol-1 -yloxytris(pyrrolidino)-phosphonium hexafluorophosphate
PyBOP benzotriazol-1 -yloxytris(pyrrolidino)-phosphonium hexafluorophosphate
Rf retention factor (thin layer chromatography)
SPECT single photon emission computed tomography
(S)SRI (selective) serotonin reuptake inhibitor TBTU O-(Benzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
THF tetrahydrofuran
EXAMPLES EXAMPLE 1 : ANALYTICAL METHODS
Nuclear magnetic resonance spectra (1H NMR and 13C NMR, APT) were determined in the indicated solvent using a Bruker ARX 400 (1H: 400 MHz, 13C: 100 MHz) at 300 K, or a Bruker (300 MHz) unless indicated otherwise. The spectra were determined in deuterated chloroform or DMSO-dβ obtained from Cambridge Isotope Laboratories Ltd. Chemical shifts (δ) are given in ppm downfield from tetramethylsilane (1H, 13C) or CCI3F (19F). Coupling constants J are given in Hz. Peakshapes in the NMR spectra are indicated with the symbols 'q' (quartet), 'dq' (double quartet), T (triplet), 'dt' (double triplet), 'd' (doublet), 'dd' (double doublet), 's' (singlet), 'br s' (broad singlet) and 'rrϊ (multiplet).
Flash chromatography/column chromatography refers to purification using indicated eluent and silica gel (either Acros: 0.030-0.075 mm or Merck silica gel 60: 0.040-0.063 mm) or if specifically stated Alumina: 'Aluminumoxide Fluka for Chromatography'; pH=9.5; 0.05-0.15 mm.
Thin layer chromatography (TLC): Merck Kieselgel 60 F254 plates 20x20 cm.
Melting points were recorded on a Bϋchi B545 melting point apparatus.
All reactions involving moisture sensitive compounds or conditions were carried out under an anhydrous nitrogen atmosphere.
Reactions were monitored by using thin-layer chromatography on silica coated plastic sheets (Merck precoated silica gel 60 F254) with the indicated eluent. Spots were visualised by UV light (254 nm) or I2.
Dichloromethane (phosphorous pentoxide and calciumhydride), tetrahydrofuran (sodium/ benzophenone ketyl) and light petroleum (60-80) were distilled freshly prior to use. All other commercially available chemicals were used without further purification.
EXAMPLE 2: GENERAL ASPECTS OF SYNTHESES
The syntheses of essential structural elements of known cannabinoid-CB-i antagonist are described in patent applications and/or scientific literature. For instance, well-documented are the essential cannabinoid structural elements (A1a) (WO01070700, Lange, 2004b), (A1b) (WO03026648), (A2) (WO03027076, WO03040107, WO03063781, Lange, 2005b; Dyck (2004), (A3) (EP0576357, EP1150961, Lan, 1999; Seltzman, 1995; Dutta, 1994 and Katoch-Rouse, 2003), (A4) (WO03007887, Plummer, 2005), (A5) (WO0307069), (A6) (WO03078413, Lange, 2005b), (A7) (WO2004026301, Lange, 2005b; Dyck, 2004) and (A8) (WO2004013120).
From a general viewpoint the synthesis of compounds of formula (1 ) wherein R represents a hydrogen atom can be accomplished by reacting a compound of general formula A-L wherein L represents a leaving group with a compound of general formula HRN-TB. It will be obvious for those skilled in the art that the amino group present in HRN-TB must be sufficiently nucleophilic in order to displace the leaving group from A-L in such a reaction. In the case that L represents a hydroxy group which is part of a carboxylic acid group, activating or coupling reagents may be added in order to enhance the reaction rate (Bodanszky, 1994; Akaji, 1994; Albericio, 1997; Montalbetti, 2005).
The synthesis of compounds of the general formula (1 ) wherein A represents the cannabinoid structural element of structure (A1a) or (A1b) wherein R1, R2 and R3 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms, is outlined in Scheme 3.
Figure imgf000024_0001
(A^) (A«) (1 )
Figure imgf000024_0002
(A1b1) (A1b2) (1 )
Scheme 3
A compound of general formula (A1a1) can be reacted with POCI3 in the presence of DMAP in an inert organic solvent such as dichloromethane to give the corresponding derivative of general formula (A1a2). This compound of general formula (A1a2) can be reacted with a compound of general formula HRN-TB. This reaction can give a compound of general formula (1 ) wherein A has the meaning as given herein above for (A1a) and wherein R, N, T and B have the abovementioned meaning, Analogously, a compound of general formula (A1b1) can be reacted with POCI3 in the presence of DMAP in an inert organic solvent such as dichloromethane to give the corresponding chloride derivative of general formula (A1b2). This compound of general formula (A1b2) can be reacted with a compound of general formula HRN-TB. This reaction can give a compound of general formula (1 ) wherein A has the meaning as given herein above for (A1b) and wherein R, N, T and B have the abovementioned meaning.
The synthesis of compounds of the general formula (1 ) wherein A represents the cannabinoid structural element of structure (A2) is outlined in Scheme 4.
Figure imgf000025_0001
(A*
(1 ) wherein A is derived from A2 basic hydrolysis OH-
Figure imgf000025_0002
(A2'2) (1 ) wherein A is derived from A2
SOCI2 or oxalyl chloride
Figure imgf000025_0003
(A2' (1 ) wherein A is derived from A2
Scheme 4 In Scheme 4, R1 and R2 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms, R4 represents a hydrogen or halogen atom or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methyl- sulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, d-3-dialkyl-aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1 -ylmethyl, morpholin-4-ylmethyl and the other symbols have the meanings as given above.
An ester of general formula (A2'1) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A2. Such a reaction can be catalyzed by trimethylaluminum (AIMe3) (Levin, 1982). Alternatively, a compound of general formula (A2'1) can be hydrolyzed into the corresponding carboxylic acid of general formula (A2'2). A compound of general formula (A2'2) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A2. This reaction preferably proceeds via activating and coupling methods such as formation of an active ester, or in the presence of a so-called coupling reagent, for example, DCC, HBTU, TBTU, HOAt, PyBOP, BOP, CIP, 2-chloro-1 ,3- dimethyl-imidazolinium chloride, PyAOP and the like.
Alternatively, a compound of general formula (A2'2) can be converted in the presence of a chlorinating agent such as thionyl chloride or oxalyl chloride into the corresponding acid chloride of general formula (A2'3). A compound of general formula (A2'3) can be reacted with a compound of general formula HRN-TB to give a compound of general formula (1 ) wherein part A is derived from substructure A2. A base like DIPEA can be added to the reaction mixture to scavenge the liberated hydrochloric acid or excess HRN-TB can be applied for this purpose.
Analogously, the substructures of general formula (A3) (A4), (A5), (A6), (A7), or (A8), as given above, can be converted into compounds of the general formula (1 ) wherein part A is derived from the substructures (A3) (A4), (A5), (A6), (A7), or (A8) respectively.
The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid or an organic acid. EXAMPLE 3: SYNTHESES OF INTERMEDIATES
Intermediate A: 4-chloro-1-(5-fluoro-1H-indol-3-yl)-butan-1-one
Intermediate A
Figure imgf000027_0001
To a magnetically stirred mixture Of AICI3 (25 g, 0.19 mol) in dichloromethane was slowly added 4-chloro-butyryl chloride (21 ml, 0.19 mol) at 0 0C. The resulting mixture was stirred for 30 minutes and 5-fluoro-1 H-indole (25 g, 0.19 mol) was slowly added. After stirring for another 30 minutes the formed orange mixture was poured onto concentrated hydrochloric acid (140 ml) and ice (200 ml) to give a pink precipitate. The precipitate was collected by filtration to give pink 4-chloro-1-(5-fluoro-1 H-indol-3-yl)-butan-1-one (29 gram, 65 % yield).
1H-NMR (400 MHz, DMSOd6) δ 2.09 (quintet, J = 7, 2H), 3.02 (t, J = 7, 2H), 3.70 (t, J = 7, 2H), 7.07 (dt, J ~ 9 and 2, 1 H), 7.49 (dd, J ~ 9 and 4, 1 H), 7.85 (dd, J ~ 9 and 2, 1 H), 8.41 (d, J ~ 3, 1 H), 12.21 (br s, 1 H).
Intermediate B: 4-[4-(5-fluoro-1 H-indol-3-yl)-4-oxobutyl]-piperazine-1 -carboxylic acid tert- butyl ester
Intermediate B
Figure imgf000027_0002
To a magnetically stirred solution of 4-chloro-1-(5-fluoro-1 H-indol-3-yl)-butan-1-one (10.93 g, g, 45.6 mmol) in acetonitrile (100 ml) was added piperazine (20.33 g ml, 236 mmol) and a small amount of potassium iodide (0.1 gram) and the resulting mixture was heated at 80 0C for 48 hours. The formed solid material was removed by filtration and the residue was concentrated in vacuo to give 37 gram crude yield. This crude product was further purified by column chromatography (gradient: ethylacetate/methanol/25% aqueous ammonia = 90/5/5 to methanol) to give 17.1 gram crude 1-(5-fluoro-1 H-indol-3-yl)-4-(piperazin-1-yl)-butan-1-one. 10.71 Gram (0.389 mol) of this crude 1-(5-fluoro-1 H-indol-3-yl)-4-(piperazin-1-yl)-butan-1-one was dissolved in dichloromethane (500 ml) and BoC2O (25.53 g, 0.1 17 mol) was added. The resulting mixture was stirred for 4 hours at room temperature. The mixture was successively washed with 5 % aqueous NaHCO3 and water. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. Subsequent column chromatography (gradient: dichloro- methane/methanol = 99/1 to dichloro-methane/methanol = 90/10 (v/v)) gave pure 4-[4-(5-fluoro- 1 H-indol-3-yl)-4-oxobutyl]-piperazine-1-carboxylic acid tert-butyl ester (3.85 gram, 37 % yield). 1H-NMR (400 MHz, DMSOd6) δ 1.38 (s, 9H), 1.80 (quintet, J = 7, 2H), 2.25-2.35 (m, 6H), 2.84 (t, J = 7, 2H), 3.22-3.32 (m, 4H), 7.06 (dt, J ~ 9 and 3, 1 H), 7.47 (dd, J ~ 9 and 5, 1 H), 7.85 (dd, J ~ 9 and 3, 1 H), 8.38 (s, 1 H), 12.01 (br s, 1 H).
Intermediate C: 5-fluoro-3-[4-(piperazin-1 -yl)butyl]-1 H-indole
/— _/N\^/ Intermediate C
H
To a magnetically stirred solution of 4-[4-(5-fluoro-1 H-indol-3-yl)-4-oxobutyl]-piperazine-1- carboxylic acid tert-butyl ester (3.85 gram, 9.88 mmol) in dichloromethane was added hydrochloric acid (dissolved in dioxane: 4.94 ml, 4M solution, 19.8 mmol HCI) and the resulting mixture was reacted at room temperature for 4 hours. The reaction mixture was thoroughly concentrated in vacuo to give 1-(5-fluoro-1 H-indol-3-yl)-4-(piperazin-1-yl)butan-1-one dihydrochloride (3.20 gram). Some characteristic 1H-NMR signals from 1-(5-fluoro-1 H-indol-3- yl)-4-(piperazin-1-yl)butan-1-one dihydrochloride: (400 MHz, DMSOd6) δ 2.07 (quintet, J = 7, 2H), 3.03 (t, J = 7, 2H), 7.08 (dt, J ~ 9 and 3, 1 H), 7.50 (dd, J ~ 9 and 4, 1 H), 7.85 (dd, J ~ 9 and 3, 1 H), 8.43 (d, J ~ 3, 1 H), 12.21 (br s, 1 H).
The obtained 1-(5-fluoro-1 H-indol-3-yl)-4-(piperazin-1-yl)butan-1-one dihydrochloride (3.20 gram) was dissolved in tetrahydrofuran (50 ml) and cooled to 0 0C. A solution of LiAIH4 in tetrahydrofuran (60 ml; 1 M, - 53 mmol LiAIH4) was slowly added. Subsequently, the mixture was heated at 80 0C for 20 hours. The excess LiAIH4 was cautiously hydrolyzed and after extractive work-up 5-fluoro-3-[4-(piperazin-1-yl)butyl]-1 H-indole (2.39 gram, 98 % yield) was obtained. 1H-NMR (400 MHz, DMSOd6) δ 1.40-1.50 (m, 2H), 1.61 (quintet, J = 7, 2H), 2.12-2.35 (m, 7H), 2.60-2.70 (m, 6H), 6.85-6.92 (m, 1 H), 7.17 (d, J ~ 2, 1 H), 7.23 (dd, J ~ 9 and 2, 1 H), 7.30 (dd, J ~ 9 and 4, 1 H), 10.85 (br s, 1 H). Intermediate D: 7-(tetrahydropyran-2-yloxy)-1 -[4-(trifluoromethyl)phenyl]heptan-1 -one
Intermediate D
Figure imgf000029_0001
Magnesium (1.20 g, 0.0494 mol) was added to anhydrous THF (5 ml) and at reflux temperature were successively added 1 ,2-dibromoethane (1 ml), a small crystal of iodine and 2-(6- chlorohexyloxy)tetrahydro-2-pyran (10.0 gram, 0.0453 mol; dissolved in 9 ml of THF) and the resulting mixture was heated at reflux temperature for 30 minutes. 4-Trifluoromethylbenzonitrile (7.0 gram, 0.0412 mol: dissolved in 8 ml toluene) was slowly added and the mixture was heated for another 30 minutes. The mixture was allowed to attain room temperature and quenched with acetic acid (30 ml). The organic layer was separated and successively washed with water, 5 % aqueous NaHCC>3, water (twice) and brine. The organic layer was dried over Na2SC>4, filtered and concentrated in vacuo. Subsequent column chromatography (ethylacetate/ heptane = 10/90 (v/v)) gave pure 7-(tetrahydropyran-2-yloxy)-1-[4-(trifluoromethyl)phenyl]heptan-1-one (10.92 gram, 74 %) as an oil. Rf = 0.25 (ethylacetate/ heptane = 1/6 (v/v).
1H-NMR (400 MHz, CDCI3) δ 1.39-1.88 (m, 14H), 3.00 (t, J = 7, 2H), 3.36-3.43 (m, 1 H), 3.47- 3.52 (m, 1 H), 3.71-3.77 (m, 1 H), 3.83-3.90 (m, 1 H), 4.56-4.58 (m, 1 H), 7.73 (d, J ~ 8, 2H), 8.06 (d, J - 8, 2H).
Intermediate E: toluene-4-sulfonic acid 7-oxo-7-[4-(trifluoromethyl)phenyl]heptyl ester
Intermediate E
Figure imgf000029_0002
To a magnetically stirred solution of 7-(tetrahydropyran-2-yloxy)-1-[4-(trifluoromethyl) phenyl]heptan-1-one (7.70 gram, 0.0215 mol) in methanol (50 ml) was added para- toluenesulfonic acid hydrate (4.18 gram, 0.022 mol). The resulting acidic mixture (pH ~ 2, pH paper) was reacted at room temperature for 20 hours. NaOH (1 N) was added until the solution was neutral (pH ~ 7, pH paper) and the resulting mixture was concentrated in vacuo. NaOH
(1 N, 50 ml) was added and the mixture was extracted with dichloromethane (3x). The combined organic layers were successively washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give crude 7-hydroxy-1-[4-
(trifluoromethyl)phenyl]heptan-1-one (5.85 g, 99 % yield) as a white solid. This obtained solid was treated with pyridine (29.6 ml) and a solution of tosyl chloride (17.72 gram, 0.093 mol) in pyridine (89 ml) was added at 0 0C. The mixture was allowed to attain room temperature and reacted for 1 hour. The mixture was cooled at -10 0C and quenched with excess water. Extraction with diethyl ether (3x), followed by drying over Na2SC>4, filtering and concentration in vacuo gave crude product which was purified by column chromatography (dichloromethane/ heptane = 2/1 (v/v)) to give pure toluene-4-sulfonic acid 7-oxo-7-[4-(trifluoromethyl)phenyl]heptyl ester (7.91 gram, 87 % yield). 1H-NMR (400 MHz, CDCI3) δ 1.35-1.38 (m, 4H), 1.57-1.73 (m, 4H), 2.44 (s, 3H), 2.97 (t, J = 7, 2H), 4.03 (t, J = 7, 2H), 7.35 (d, J ~ 8, 2H), 7.73 (d, J ~ 8, 2H), 7.79 (d, J ~ 8, 2H), 8.04 (d, J ~ 8, 2H).
Intermediate F: toluene-4-sulfonic acid 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl ester
Intermediate F
Figure imgf000030_0001
To a magnetically stirred solution of toluene-4-sulfonic acid 7-oxo-7-[4-(trifluoromethyl) phenyl]heptyl ester (2.77 gram, 6.464 mmol) in methanol (75 ml) were successively added a catalytic amount of para-toluenesulfonic acid (0.097 gram, 0.508 mmol) and excess trimethylorthoformate (16 ml, 142 mmol). The resulting mixture was heated at reflux temperature for 20 hours. After allowing the reaction mixture to attain room temperature saturated aqueous NaHCO3 and dichloromethane were successively added. The separated organic layer was washed with saturated aqueous NaHCO3. The organic layer was subsequently dried over Na2SO4, filtered and concentrated in vacuo to give crude toluene-4- sulfonic acid 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl ester which was purified by column chromatography (alumina, ethylacetate/ heptane = 1/10 (v/v)) to give pure toluene-4- sulfonic acid 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl ester (1.82 gram, 59 % yield). 1H- NMR (400 MHz, CDCI3) δ 0.84-0.93 (m, 2H), 1.06-1.26 (m, 4H), 1.51-1.57 (m, 2H), 1.80-1.86 (m, 2H), 2.44 (s, 3H), 3.13 (s, 6H), 3.94 (t, J = 7, 2H), 7.32 (d, J ~ 8, 2H), 7.55 (d, J ~ 8, 2H), 7.60 (d, J ~ 8, 2H), 7.75 (d, J ~ 8, 2H). Intermediate G: 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptylamine
Intermediate G
Figure imgf000031_0001
Toluene-4-sulfonic acid 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl ester (1.82 gram, 3.835 mmol) was dissolved in a magnetically stirred solution of 7 M NH3 in methanol (30 ml) and stirred at room temperature for 72 hours. After removal of the solvent in vacuo the residue was dissolved again in dichloromethane and washed with saturated aqueous NaHCC>3. The organic layer was subsequently dried over Na2SO4, filtered and concentrated in vacuo to give crude 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptylamine (1.43 gram) which was not further purified. 1H-NMR (400 MHz, CDCI3) δ 0.88-0.95 (m, 2H), 1.12-1.16 (m, 4H), 1.33-1.38 (m, 2H), 1.83-1.88 (m, 2H), 2.59-2.65 (m, 2H), 3.10-3.26 (m, 8H, including -OMe singlet at 3.14), 7.56 (d, J - 8, 2H), 7.60 (d, J - 8, 2H).
EXAMPLE 4: SYNTHESES OF SPECIFIC COMPOUNDS
The specific compounds of which the synthesis is described below are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict the scope of the invention in any way. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is thus intended that the specification and examples be considered as exemplary only.
N-{1 -[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl] heptylamino]-1 -[3-(4- chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-methylidene}-4-chloro- benzenesulfonamide (compound 1 )
1
Figure imgf000031_0002
Part A: 3-(4-Chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4-phenyl-4,5-dihydro-1 H-pyrazole-1- carboxamide was obtained as described {Lange, 2004b). 3-(4-Chloro-phenyl)-N-[(4-chloro- phenyl)sulfonyl]-4-phenyl-4,5-dihydro-1 H-pyrazole-1-carboxamid (0.708 gram, 1.493 mol) was dissolved in anhydrous dichloromethane (15 ml) and DMAP (0.820 gram, 6.716 mmol) and POCI3 (0.209 g, 2.238 mmol) were successively added and the resulting mixture was refluxed for 5 hours. The mixture was cooled at 0 0C. 7,7-Dimethoxy-7-[4-(trifluoromethyl)phenyl]- heptylamine (1.43 gram, 4.477 mmol) and DIPEA (0.740 ml, 4.48 mmol) were successively added. The mixture was subsequently heated at reflux temperature for 30 hours. The mixture was allowed to attain room temperature and was washed with 5 % aqueous NaHCC>3, dried over Na2SO4, filtered and concentrated in vacuo. The obtained crude product was purified by column chromatography (alumina; gradient: heptane/ethylacetate = 6/1 to ethylacetate to ethylacetate/ methanol = 95/5 (v/v)) to give pure 4-chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5- dihydro-1 H-pyrazol-1 -yl]-[7-(4-fluorophenyl)-7,7-dimethoxyheptylamino] methylene}benzenesul fonamide (0.200 gram, 17 % yield). 1H-NMR (400 MHz, CDCI3) δ 0.91-1.01 (m, 2H), 1.17-1.28 (m, 4H), 1.49-1.57 (m, 2H), 1.85-1.92 (m, 2H), 3.15 (s, 6H), 3.50-3.58 (m, 2H), 4.04-4.13 (m, 1 H), 4.47-4.65 (m, 2H), 7.10 (d, J ~ 8, 2H), 7.22-7.32 (m, 5H) 7.35 (d, J ~ 8, 2H), 7.48 (d, J ~ 8, 2H), 7.58 (d, J ~ 8, 2H), 7.61 (d, J ~ 8, 2H), 7.82 (d, J ~ 8, 2H), invisible NH proton.
Part B: 4-Chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-[7-(4-fluoro- phenyl)-7,7-dimethoxyheptylamino] methylene}-benzenesulfonamide (0.200 gram, 0.258 mmol) was dissolved in a 1 :1 mixture of THF/methanol (30 ml) and 5 ml 1 N hydrochloric acid was added and the resulting mixture was stirred at room temperature for 20 hours. The mixture was quenched with 5 % aqueous NaHCO3. Most of the THF and methanol were removed by evaporation in vacuo. The remaining water layer was twice extracted with ethylacetate. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The obtained crude 4-chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-[7-(4- fluorophenyl)-7-oxo-heptylamino] methylene}benzenesulfonamide (203 mg) was not further purified. Some characteristic aromatic 1H-NMR signals: (400 MHz, CDCI3) δ 7.12 (d, J - 8, 2H),
7.22-7.33 (m, 5H) 7.39 (d, J ~ 8, 2H), 7.50 (d, J ~ 8, 2H), 7.72 (d, J ~ 8, 2H), 7.84 (d, J ~ 8, 2H), 8.05 (d, J ~ 8, 2H).
Part C: 4-Chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-[7-(4-fluoro- phenyl)-7-oxo-heptylamino] methylene}benzenesulfonamide (0.203 gram, 0.278 mmol) was dissolved in absolute ethanol (10 ml) and O-(2-aminoethyl)hydroxylamine dihydrochloride (61 mg, 1.5 mol equivalent) and pyridine (0.04 ml) were successively added. The resulting mixture was stirred at reflux temperature for 20 hours. The mixture was allowed to attain room temperature. After removal of the solvent in vacuo the residue was dissolved in dichloromethane and washed successively with an aqueous KHSO4 solution and brine. The organic layer was subsequently dried over Na2SC>4, filtered and concentrated in vacuo to give N- {1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4- phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-methylidene}-4-chloro-benzenesulfonamide (Compound 1 ) (0.231 gram) as a mixture of E/Z stereoisomers Melting point: 53-58 0C. 1H-NMR (400 MHz, CDCI3) δ 1.30-1.67 (m, 8H), 2.80 (t, J = 7, 2H), 3.33-3.40 (m, 2H), 3.56-3.66 (m, 2H), 4.03 (dd, J = 1 1 and 5, 1 H), 4.43-4.55 (m, 3H), 4.60-4.70 (m, 2H), 7.10 (d, J ~ 8, 2H), 7.20-7.37 (m, 7H) 7.48 (d, J ~ 8, 2H), 7.58 (d, J ~ 8, 2H), 7.71 (d, J ~ 8, 2H), 7.82 (d, J ~ 8, 2H), 8.60 (br s, 2H).
2-(2-Chlorophenyl)-1 -(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid [7-(2-amino- ethoxyimino)-7-[4-(trifluoromethyl)phenyl] heptyl]amide (comp. 2)
Compound 2
Figure imgf000033_0001
Part A: Ethyl 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylate was obtained according to WO03040107. To a magnetically stirred solution of ethyl 2-(2- chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylate (5.80 g, 0.0149 mol) in tetrahydrofuran (40 ml) was added a solution of LiOH (0.715 g) in water (40 ml). The resulting mixture was heated at 70 0C for 16 hours. The resulting mixture was allowed to attain room temperature and subsequently treated with concentrated hydrochloric acid (3.5 ml). The tetrahydrofuran was evaporated in vacuo and the resulting mixture was stirred overnight. The formed precipitate was collected by filtration and washed with petroleum ether (40-60) to give 2- (2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid (4.52 gram, 84 % yield). 1H-NMR (400 MHz, CDCI3): δ 1.09 (t, J = 7, 3H), 2.90 (q, J = 7, 2H), 3.70 (br s, 1 H), 7.12 (dt, J = 8 and 2, 2H), 7.22-7.28 (m, 1 H), 7.29-7.38 (m, 5H).
Part B: 2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid (1.48 g, 4.123 mmol), 7-amino-1-(4-(trifluoromethyl)phenyl)heptan-1-one (1.127 g, 4.123 mmol) (7- amino-1-(4-(trifluoromethyl)phenyl)heptan-1-one was obtained in 62 % yield from intermediate E (toluene-4-sulfonic acid 7-oxo-7-[4-(trifluoromethyl) phenyl]heptyl ester) using 7M NH3 in methanol; 72 hours at room temperature, analogously to the synthesis of intermediate G (see also Teubner, 1993), EDCI, HOAt (0.67 gram, 4.95 mmol) and DIPEA (1.44 ml, 8.246 mmol) were successively dissolved in dichloromethane (30 ml) and magnetically stirred at room temperature for 70 hours. The reaction mixture was washed successively with water, 5 % aqueous NaHCO3 solution and water and was subsequently dried over Na2SO4, filtered and concentrated in vacuo to give crude 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole- 4-carboxylic acid {7-[4-(trifluoromethyl)phenyl]-7-oxo-heptyl}amide which was purified by column chromatography (alumina; heptane/ethylacetate = 4/1 (v/v)), followed by another column chromatography (silicagel; heptane/ethylacetate = 4/1 (v/v)) to give pure 2-(2- chlorophenyl)-1 -(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid {7-[4-(trifluoromethyl)- phenyl]-7-oxo-heptyl}amide (1.28 gram, 50 % yield). 1H-NMR (300 MHz, DMSO-d6): δ 0.92 (t, J = 7, 3H), 1.28-1.68 (m, 8H), 2.84 (q, J = 7, 2H), 3.08 (t, J = 7, 2H), 3.23 (q, J = 7, 2H), 7.30-7.42 (m, 5H), 7.49 (br d, J = 8, 2H), 7.56 (d, J = 8, 2H), 7.89 (d, J = 8, 2H), 8.04 (t, J = 6, 1 H), 8.15 (d, J = 8, 2H).
Part C: 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid {7-[4- (trifluoromethyl)phenyl]-7-oxo-heptyl}amide (1.15 gram, 1.86 mmol) was dissolved in absolute ethanol (10 ml) and O-(2-aminoethyl)hydroxylamine dihydrochloride (0.276 mg, 1.865 mol) and pyridine (0.18 ml) were successively added. The resulting mixture was stirred at reflux temperature for 20 hours. The mixture was allowed to attain room temperature. After removal of the solvent in vacuo the residue was dissolved in dichloromethane and washed successively with an aqueous KHSO4 solution and brine. The organic layer was subsequently dried over Na- 2SO4, filtered and concentrated in vacuo to give 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl- 1 H-imidazole-4-carboxylic acid [7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl] heptyl]- amide (Compound 2) (1.34 gram) as a mixture of E/Z stereoisomers. Melting point: 90-95 0C. 1H-NMR (400 MHz, CDCI3) δ 1.05 (t, J = 7, 3H), 1.34-1.62 (m, 8H), 2.81 (br t, J = 7, 2H), 2.93 (q, J = 7, 2H), 3.32-3.42 (m, 4H), 4.44-4.50 (m, 2H), 7.1 1 (d, J = 8, 2H), 7.21-7.34 (m, 5H), 7.37 (d, J = 8, 1 H), 7.49 (br s, 1 H), 7.59 (d, J = 8, 2H), 7.71 (d, J = 8, 2H), 8.65 (br s, 2H).
[2-(2-Chlorophenyl)-1 -(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-yl] {4-[4-(5-fluoro-1 H-indol- 3-yl)butyl]piperazin-1 -yl}methanone (compound 3)
Compound 3
Figure imgf000034_0001
2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid (0.880 g, 2.44 mmol) was reacted with intermediate C (5-fluoro-3-[4-(piperazin-1-yl)butyl]-1 H-indole), EDCI, HOAt and K2CO3 (1.55 mol equivalent) in dichloromethane (30 ml) at room temperature for 70 hours analogously to the procedure described to prepare compound 2, Part B to give [2-(2- chlorophenyl)-1 -(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-yl] {4-[4-(5-fluoro-1 H-indol-3-yl)butyl]- piperazin-1-yl}methanone (compound 3) (704 mg, 76 % yield) (1.28 gram, 50 % yield). Melting point: 91-92 0C. 1H-NMR (400 MHz, CDCI3) δ 1.03 (t, J = 7, 3H), 1.57-1.76 (m, 4H), 2.42 (t, J = 7, 2H), 2.48-2.58 (m, 4H), 2.72 (t, J = 7, 2H), 2.77 (q, J = 7, 2H), 3.81 (br s, 2H), 4.08 (br s, 2H), 6.91 (dt, J ~ 8 and 2, 1 H), 7.01 (d, J = 2, 1 H), 7.10 (d, J = 8, 2H), 7.15-7.35 (m, 8H), 8.08 (br s, 1 H).
4-Chloro-N-{[1 -[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-1 -{4-[4-(5-fluoro- 1 H-indol-3-yl)butyl]piperazin-1 -yl} methylidene]-benzenesulfon-amide (compound 4)
Compound 4
Figure imgf000035_0001
3-(4-Chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4-phenyl-4,5-dihydro-1 H-pyrazole-1- carboxamide (0.950 gram, 2.00 mmol) was dissolved in anhydrous dichloromethane and reacted with DMAP and POCI3, followed by a reaction with intermediate C (5-fluoro-3-[4- (piperazin-1 -yl)butyl]-1 H-indole) and DIPEA analogously to the procedure to prepare compound 1 , Part A to give 4-chloro-N-{[1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-1 -{4- [4-(5-fluoro-1 H-indol-3-yl)butyl]piperazin-1-yl}methylidene]-benzenesulfonamide, (compound 4) (660 mg, 45 % yield). Melting point: 98-102 0C. 1H-NMR (400 MHz, CDCI3) δ 1.56-1.66 (m, 2H), 1.70-1.80 (m, 2H), 2.47 (t, J = 7, 2H), 2.57-2.70 (m, 4H), 2.75 (t, J = 7, 2H), 3.69-3.86 (m, 5H), 4.42 (t, J = 1 1 , 1 H), 4.54 (dd, J = 1 1 and 5, 1 H), 6.93 (dt, J ~ 8 and 2, 1 H), 7.03 (d, J ~ 2, 1 H), 7.10 (d, J = 8, 2H), 7.21-7.38 (m, 8H), 7.48 (d, J = 8, 2H), 7.83 (d, J = 8, 2H), 7.98 (br s, 1 H). EXAMPLE 5: FORMULATIONS USED IN ANIMAL STUDIES
For oral (p.o.) administration: to the desired quantity (0.5-5 mg) of the solid compound 1 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1 % methylcellulose in water and 2% (v/v) of Poloxamer 188 (Lutrol F68), the compound was suspended by vortexing for 10 minutes. The pH was adjusted to 7 with a few drops of aqueous NaOH (0.1 N). Remaining particles in the suspension were further suspended by using an ultrasonic bath.
For intraperitoneal (Lp.) administration: to the desired quantity (0.5-15 mg) of the solid compound 1 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1 % methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
EXAMPLE 6: PHARMACOLOGICAL METHODS
In vitro affinity for human cannabinoid-CE÷H receptors
The affinity of the compounds of the invention for cannabinoid CB1 receptors can be determined using membrane preparations of CHO cells in which the human cannabinoid CB1 receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
In vitro affinity for serotonin reuptake sites
Affinity of the compounds for serotonin reuptake sites was determined using the receptor binding assay described (Habert, 1985).
EXAMPLE 7: PHARMACOLOGICAL TESTRESULTS
Cannabinoid-CB-i receptor affinity data and serotonin reuptake inhibition data obtained according to the protocols given above are shown in the table below.
Figure imgf000037_0003
Figure imgf000037_0001
Figure imgf000037_0002
compound A
The data given above indicate that the compounds of the invention have a high affinity for both CB1 receptors and 5-HT reuptake sites. Their affinity for CB1 receptors is as high as that of rimonabant, whilst e.g. compound 1 simultaneously is as potent a serotonin reuptake inhibitor as fluoxetine. This in sharp contrast with for instance a structurally closely related potent CB1 antagonist disclosed in WO 03/027076 (see structure above) which is completely inactive as serotonin reuptake inhibitor. Other CB1 antagonists tested are devoid of affinity for 5-HT reuptake sites, and the 5-HT reuptake inhibitors tested do not have affinity for CB1 receptors. EXAMPLE 8: PHARMACEUTICAL PREPARATIONS
For clinical use, compounds of formula (1 ) are formulated into pharmaceutical compositions that are important and novel embodiments of the invention because they contain the compounds, more particularly specific compounds disclosed herein. Types of pharmaceutical compositions that may be used include, but are not limited to, tablets, chewable tablets, capsules (including microcapsules), solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, and other types disclosed herein, or are apparent to a person skilled in the art from the specification and general knowledge in the art. The active ingredient for instance, may also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters. The compositions are used for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or other ways to administer. The pharmaceutical formulation contains at least one compound of formula (1 ) in admixture with at least one pharmaceutically acceptable adjuvant, diluent and/or carrier. The total amount of active ingredients suitably is in the range of from about 0.1% (w/w) to about 95% (w/w) of the formulation, suitably from 0.5% to 50% (w/w) and preferably from 1% to 25% (w/w). In some embodiments, the amount of active ingredient is greater than about 95% (w/w) or less than about 0.1 % (w/w).
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxiliary substances include magnesium carbonate, titanium dioxide, lactose, saccharose, sorbitol, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, amylopectin, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets. A tablet is prepared using the ingredients below:
Ingredient Quantity (mg/tablet)
COMPOUND No. 1 10
Cellulose, microcrystalline 200
Silicon dioxide, fumed 10 Stearic acid 1P_
Total 230 The components are blended and compressed to form tablets each weighing 230 mg.
The active ingredients may be separately premixed with the other non-active ingredients, before being mixed to form a formulation. The active ingredients may also be mixed with each other, before being mixed with the non-active ingredients to form a formulation.
Soft gelatin capsules may be prepared with capsules containing a mixture of the active ingredients of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. Hard gelatin capsules may contain granules of the active ingredients. Hard gelatin capsules may also contain the active ingredients together with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
Dosage units for rectal administration may be prepared (i) in the form of suppositories that contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule that contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
Liquid preparations may be prepared in the form of syrups, elixirs, concentrated drops or suspensions, e.g. solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations may also be prepared in the form of a dry powder, reconstituted with a suitable solvent prior to use. Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation, reconstituted with a suitable solvent before use.
Also provided according to the invention are formulations and 'kits of parts' comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention, for use in medical therapy. Associated with such container(s) can be written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration. The use of formulations of the invention in the manufacture of medicaments for treating a condition wherein antagonism of CB1 receptors and/or inhibition of serotonin re-uptake is required or desired, and methods of medical treatment or comprising the administration of a therapeutically effective total amount of at least one compound of formula (1 ), either as such or, in the case of prodrugs, after administration, to a patient suffering from, or susceptible to, a condition wherein antagonism of CB1 receptors and/or inhibition of serotonin re-uptake is required or desired
By way of example, not of limitation, several pharmaceutical compositions are given, comprising preferred active compounds for systemic use or topical application. Other compounds of the invention or combinations thereof, may be used in place of (or in addition to) said compounds. The concentration of the active ingredient may be varied over a wide range as discussed herein. The amounts and types of ingredients that may be included are well known in the art.
BIBLIOGRAPHY
Akaji, K. et al., Tetrahedron Lett. (1994), 35, 3315-3318
Albericio, F. et al., Tetrahedron Lett. (1997), 38, 4853-4856
Berge, S. M.: "Pharmaceutical salts", J. Pharmaceutical Science, 66, 1-19 (1977). Bickel, M. H., : "The pharmacology and Biochemistry of N-oxides", Pharmacological Reviews, 21(4), 325 - 355, 1969.
Bodanszky, M. and A. Bodanszky: The Practice of Peptide Synthesis, Springer-Verlag, New
York, 1994; ISBN: 0-387-57505-7
Bundgaard, H. (editor), "Design of Prodrugs", Elsevier, 1985.
Bureau, R. et al., J. Chem. Inf. Comput. Sci. 2002, 42, 429-436 Byrn et al., Pharmaceutical Research, 12(7), 945-954, 1995. De Petrocellis, L. et al,. Br. J. Pharmacol. 2004, 141 , 765-774.
Di Marzo, V. et al., Nature Rev. Drug Discov. 2004, 3, 771-784.
Dutta, A.K. et al., Med. Chem. Res. 1994, 5, 54-62
Dwyer & Meilor,: "Chelating agents and Metal Chelates", Academic Press, chapter 7, 1964. Dyck, B. et al., Bioorg. Med. Chem. Lett. 2004, 14, 1 151-1 154
Ettmayer, P. et al., "Lessons learned from marketed and investigational prodrugs", J. Med. Chem., 47, 2393-2404, 2004. Habert, E. et al.,: "Characterisation of [3H]-paroxetine binding to rat cortical membranes", Eur.J.Pharmacol., 118, 107-1 14, 1985.
Hertzog, D.L. Expert Opin. Ther. Patents 2004, 14, 1435-1452; Jarvinen, T. et al., "Design and Pharmaceutical applications of prodrugs", pages 733-796 in: S. C. Gad: "Drug Discovery Handbook', John Wiley & Sons Inc., New Jersey, U.S.A., 2005.
Katoch-Rouse, R. et al., J. Med. Chem. 2003, 46, 642-645
King, F. D., (editor), page 215 in: "Medicinal Chemistry: Principles and Practice", 1994.
Lambert, D. M. and Fowler, CJ. J. Med. Chem. 2005, 48, 5059-5087 Lan, R. et al., J. Med. Chem. 1999, 42, 769-776
Landsman, R.S. et al., Eur. J. Pharmacol. 1997, 334, R1-R2
Lange, J. H. M. and Kruse, C. G., C. Curr. Opin. Drug Discovery Dev. 2004a, 7, 498-506
Lange, J. H. M. et al., J. Med. Chem. 2004b, 47, 627-643
Lange, J. H. M. and Kruse, CG. Drug Discov. Today 2005b, 10, 693-702; Lange, J. H. M. et al., J. Med. Chem. 2005b, 48, 1823-1838
Le Fur, G. and Uzan, A., Biochem Pharmacol. 1977, 26, 497-503;
Levin, J. I., E. Turos and S. M. Weinreb, Synth. Commun., 12, 989-993, 1982.
Lichtman, A.H. et al., Prostaglandins Leukotrienes and Essential Fatty Acids 2002, 66, 269-285
Malleron, J.-L. et al., J. Med. Chem. 1993, 36, 1 194-1202 Martin, E. W. (Editor), "Remington: The Science and Practice of Pharmacy", Mack Publishing Company, 19th Edition, Easton, Pa, VoI 2., Chapter 83, 1447-1462, 1995.
Montalbetti, C and V. Falque, Tetrahedron , 61 , 10827-10852, 2005 Muccioli, G. G. et al., Curr. Med. Chem. 2005, 12, 1361-1394;
Pacher, P. and Kecskemeti, V., Curr. Med. Chem. 2004, 1 1 , 925-943
Padgett, L.W. Life Sciences 2005, 77, 1767-1798;
Plummer, CW. et al., Bioorg. Med. Chem. Lett. 2005, 15, 1441-1446
Reggio, P. H., Curr. Pharm. Des. 2003, 9, 1607-1633 Seltzman, H. H. et al., J. Chem. Soc. Chem. Commun. 1995, 1549-1550 Smith, R.A. and Fathi, Z. IDrugs 2005, 8, 53-66;
Stella,J., "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 277-280, 2004.
Teubner, A. and Gerlach, H. Liebigs Ann. Chem, 1993, 161-165
Thakur, G.A. et al., Mini-Rev. Med. Chem. 2005, 5, 631-640; Vandevoorde, S. & Lambert, D. M. Curr. Pharm. Des. 2005,1 1 , 2647-68.

Claims

1. Compounds with a combination of cannabinoid-CB-i antagonism and serotonin reuptake inhibition.
2. Compounds as claimed in claim 1 having a pK-value > 6.00 in both CB1 receptor binding as well as in serotonin reuptake binding.
3. Compounds as claimed in claim 1 of formula (1 ):
R . /N /B (1 ) f\ I
or a tautomer, stereoisomer, N-oxide, isotopically-labelled analogue, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein:
- A represents an essential structural element of any known cannabinoid-CBi antagonist containing at least two phenyl rings that are independently optionally substituted with one or two substituents selected from halogen, methoxy and trifluoromethyl, said essential structural element being attached to a hydrogen bond acceptor in said cannabinoid-CBi antagonist, wherein the hydrogen bond acceptor moiety is either a carbonyl group, a sulfonyl group, or a nitrogen or oxygen atom incorporated in a heteroaromatic ring structure,
- N represents a non-basic nitrogen atom,
- T represents a saturated or unsaturated carbon chain of 0-8 atoms, wherein one carbon atom may be replaced with a nitrogen atom, optionally substituted with an (d-C3)-alkyl or CH2CF3 group, or replaced with an oxygen atom or a sulphur atom, and which chain is optionally substituted with one or more substituents selected from fluoro, amino, cyano, (Ci-C3)alkyl, (Ci-C3)alkoxy and trifluoromethyl,
- R represents hydrogen atom, or a (Ci-C3)-alkyl group, or R together with the nitrogen atom to which it is attached, and together with a part of T, forms a (C4-C7)-heterocycloalkyl or a heteroaryl group,
- B represents an essential structural element of any known serotonin reuptake inhibititor.
4. A compound as claimed in claim 3 of formula (1 ) wherein A represents an essential structural element of a cannabinoid-CB-i antagonist selected from: 1 1 C-JHU-75528, A-796260, ajulemic acid, AM 251 , AM 630, AVE-1625, CP-272871 , CP-945598, EMD-68843, GRC-10389, LY-2077855, LY-320135, NIDA-41020, O-2093, SLV319, SLV326, SR-140098, SR-144385, SR-41716A (rimonabant), surinabant, V- 24343, WIN-54461 and WIN-56098,
and wherein B represents an essential structural element of a 5-HTreUptake inhibitor selected from:
403U76, A-80426, AD-337, adinazolam, agomelatine, alaproclate, amineptine, amitriptyline, ARAK-0029, ARAK-0051 , befetupitant, befloxatone, BGC-20-1259, bicifadine, BMS-505130, brofaromine, bupropion, butriptyline, cericlamine, citalopram, CL:-275838, clomipramine, clovoxamine, CX-157, dapoxetine, desvenlafaxine, dexfenfluramine, dibenzepin, diclofensine, dosulepine, DOV-21947, DOV-102677, DOV- 216303, duloxetine, DU 125530, DuP-631 , EN-3215, EpiCept NP-1 , escitalopram, femoxetine, fluoxetine, (S)-fluoxetine, fluvoxamine, gepirone, IDN-5491 , imipramine, indalpine, iprindole, L-792239, LI-301 , litoxetine, lofepramine, LU-10134-C, LU-AA21004, lubazodone, LY-214281 , LY-367265, LY-393558, maprotiline, MCI-225, MCL-0042, McN-5652, melitracen, mianserine, milnacipran, mirtazepine, moclobemide, modafinil, nefazodone, 6-nitroquipazine, nortriptyline, NR-200s, NS-2381 , NS-2389, NS-2463, NS-
4194, NS-23459, omiloxetine, OPC-14523, opipramol, Org-6582, paroxetine, pramipexole, PRC-025, propizepine, quetiapine, quinupramine, ramelteon, R-fluoxetine, rizatriptan, robalzotan, roxindole, RS-1439, SB-649915, S-9977, SD-726, selegiline, SEP-225289, SEP-227162, sertraline, sibutramine, (S)-sibutramine, (R)- didemethylsibutramine, SLV310, SLV314, SPD-473, tramadol, trazodone, udenafil, UK-
416244, UP-23761 , VANH-36, venlafaxine, vilazodone, VML-670, VN-2222, volinanserin, WF-23, Wf-516, WL-101 1 , WL-1017, YM-922 and zimeldine, and tautomers, stereoisomers, prodrugs and N-oxides thereof, and isotopically-labelled compounds of formula (1 ), as well as pharmacologically acceptable salts, hydrates, solvates, complexes and conjugates of said compounds of formula (1 ) and its tautomers, stereoisomers, prodrugs, N-oxides or isotopically-labelled analogs.
5. A compound as claimed in claim 3 of formula (1 ) wherein A represents one of the fragments (A1a), (A1b), (A2), (A3) (A4), (A5), (A6), (A7), or (A8):
Figure imgf000044_0001
Figure imgf000044_0002
wherein, X represents a sulfonyl or a carbonyl group, the "+" symbol represents the point at which the fragment is attached to moiety N (wherein N represents a non-basic nitrogen atom) in formula (1 ), R1, R2 and R3 independently represent or more hydrogen atoms, trifluoromethyl groups or halogen atoms, R4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, Ci-3- dialkyl-aminomethyl, pyrrolidin-1 -ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group, and the NRTB sequence of formula (1 ) is one of the fragments (NTRB1), (NRTB2), (NTRB3), (NRTB4), (NTRB5), (NRTB6), (NTRB7), (NRTB8), (NTRB9) or (NRTB10):
Figure imgf000045_0001
wherein R represents a hydrogen atom or a (Ci-C3)-alkyl group.
6. A compound as claimed in claim 3 of formula (1 ) wherein A represents one of the fragments
Figure imgf000046_0001
Figure imgf000046_0002
wherein, X represents a sulphonyl or a carbonyl group, + the point at which the fragment is attached to the non-basic nitrogen atom N in formula (1 ), R1, R2 and R3 independently represent hydrogen, trifluoromethyl or halogen, R4 represents a hydrogen or halogen atom, or a methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, d-3-dialkyl-aminomethyl, pyrrolidin-1 -ylmethyl, piperidin-1-ylmethyl or morpholin-4-ylmethyl group, and the other symbols have the meanings given in claim 5.
A compound as claimed in claim 3 of formula (1 ) wherein A represents one of the fragments (A3) or (A4):
Figure imgf000046_0003
and the other symbols have the meanings as given in claim 5.
8. A compound as claimed in claim 3 of formula (1 ) selected from:
N-{1 -[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl] heptylamino]-1 -[3-(4- chlorophenyl^-phenyl^δ-dihydro-I H-pyrazol-i-yO-methylidene^-chloro- benzenesulfonamide
2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-carboxylic acid [7-(2- amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl] heptyl]amide
[2-(2-chlorophenyl)-1 -(4-chlorophenyl)-5-ethyl-1 H-imidazole-4-yl] {4-[4-(5-fluoro-1 H- indol-3-yl)butyl]piperazin-1-yl}methanone
4-chloro-N-{[1 -[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1 H-pyrazol-1 -yl]-1 -{4-[4-(5-fluoro- 1 H-indol-3-yl)butyl]piperazin-1 -yl} methylidene]-benzenesulfonamide
9. A compound as claimed in any of the claims 3-7 of formula (1 ), or a tautomer, stereoisomer, N-oxide, isotopically-labelled analogue, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, said compound being an optically active enantiomer.
10. A compound as claimed in claim 3 of formula (1 ) selected from:
Figure imgf000047_0001
1 1. A medicament, comprising a compound according to one of the claims 1-10, or a pharmacologically acceptable salt, hydrate, solvate, complex or conjugate thereof.
12. A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance, a pharmacologically active amount of at least one compound of one of the claims 1-10, or a pharmacologically acceptable salt, hydrate, solvate, complex or conjugate thereof , as an active ingredient.
13. The pharmaceutical composition according to claim 12, further comprising at least one additional therapeutic agent.
14. Use of a compound as claimed in any of the claims 1-10 to prepare a pharmaceutical composition for the treatment of addiction, alcoholism, Alzheimers disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischaemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelinisation related disorders, diabetes, diabetic neuropathy, diarrhoea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain, panic disorder, Parkinson's disease, plaque sclerosis, premature ejaculation, premenstrual syndrome, psychosexual disorder, psychosis, rheumatoid arthritis, septic shock, schizophrenia, sexual disorders, sleep disorder, spinal cord injury, stroke, Tourette's syndrome, traumatic brain injury, tremor, urinary incontinence and viral encephalitis.
15. Use as claimed in claim 14, to prepare a pharmaceutical composition for treating psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders.
PCT/EP2008/050181 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition WO2008084057A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2009007405A MX2009007405A (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition.
EA200970672A EA200970672A1 (en) 2007-01-10 2008-01-09 CONNECTIONS WITH THE COMBINATION OF CANNABINOID-SWANTAGONISM AND INHIBITION OF SEROTONIN REVERSE CAPTURE
KR1020097016686A KR20090103932A (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
AU2008204456A AU2008204456A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
EP08701345A EP2111394A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
CN200880001916A CN101809000A (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
JP2009545172A JP2010515704A (en) 2007-01-10 2008-01-09 Compound exhibiting a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
BRPI0806452-0A BRPI0806452A2 (en) 2007-01-10 2008-01-09 compounds, drug, pharmaceutical composition, and use of a compound
CA002671554A CA2671554A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
IL198999A IL198999A0 (en) 2007-01-10 2009-05-27 Compounds with a combination of cannabinobi-cb1 antagonism and serotonin reuptake inhibition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87953307P 2007-01-10 2007-01-10
US60/879,533 2007-01-10
EP07100323 2007-01-10
EP07100323.0 2007-01-10

Publications (1)

Publication Number Publication Date
WO2008084057A1 true WO2008084057A1 (en) 2008-07-17

Family

ID=40897234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050181 WO2008084057A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition

Country Status (8)

Country Link
EP (1) EP2111394A1 (en)
JP (1) JP2010515704A (en)
KR (1) KR20090103932A (en)
AU (1) AU2008204456A1 (en)
CA (1) CA2671554A1 (en)
EA (1) EA200970672A1 (en)
IL (1) IL198999A0 (en)
WO (1) WO2008084057A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502999A (en) * 2007-11-02 2011-01-27 ジェンリン ディスカバリー Cannabinoid receptor antagonist / inverse agonist useful for the treatment of metabolic disorders including obesity and diabetes
EP2640381A2 (en) * 2010-11-18 2013-09-25 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2004013120A1 (en) * 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
WO2006061374A1 (en) * 2004-12-07 2006-06-15 Solvay Pharmaceuticals B.V. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
WO2006061372A2 (en) * 2004-12-07 2006-06-15 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites
WO2006061376A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2004013120A1 (en) * 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
WO2006061374A1 (en) * 2004-12-07 2006-06-15 Solvay Pharmaceuticals B.V. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
WO2006061372A2 (en) * 2004-12-07 2006-06-15 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites
WO2006061376A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502999A (en) * 2007-11-02 2011-01-27 ジェンリン ディスカバリー Cannabinoid receptor antagonist / inverse agonist useful for the treatment of metabolic disorders including obesity and diabetes
EP2640381A2 (en) * 2010-11-18 2013-09-25 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
EP2640381A4 (en) * 2010-11-18 2014-05-21 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Also Published As

Publication number Publication date
KR20090103932A (en) 2009-10-01
IL198999A0 (en) 2010-02-17
CA2671554A1 (en) 2008-07-17
AU2008204456A1 (en) 2008-07-17
JP2010515704A (en) 2010-05-13
EA200970672A1 (en) 2010-02-26
EP2111394A1 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
EP2091939B1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
US8138174B2 (en) Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
EP2029548A1 (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
CA2632582A1 (en) 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
BRPI0806452A2 (en) compounds, drug, pharmaceutical composition, and use of a compound
WO2008084057A1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US20110053983A1 (en) (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
US8461184B2 (en) Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
US8063062B2 (en) Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
EP2203427A2 (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
BRPI0721060A2 (en) COMPOUND, PROCESS FOR PREPARING COMPOUND, MEDICINE, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND
BRPI0711902A2 (en) compounds, pharmaceutical composition, method for preparing pharmaceutical compositions, use of a compound, and process for preparing compounds
CA2727146A1 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity
AU2008263915A1 (en) 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880001916.1

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701345

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 198999

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2671554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12009501110

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008204456

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009545172

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3980/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008701345

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/007405

Country of ref document: MX

Ref document number: 2009071061

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008204456

Country of ref document: AU

Date of ref document: 20080109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2009000471

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200970672

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A200908370

Country of ref document: UA

Ref document number: 1020097016686

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0806452

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090629